Autophagy-inducing peptides

Conjugating Beclin-1 derived peptides with a cell-penetrating peptide and endosomal escape domain addresses the poor permeability and selectivity issues of existing autophagy-inducing agents, achieving enhanced autophagy induction and therapeutic efficacy in neurodegenerative disease treatment.

WO2024243639A1PCT designated stage expired Publication Date: 2024-12-05THE FLOREY INST OF NEUROSCIENCE & MENTAL HEALTH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/AU2024/050571
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-31
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current therapies for neurodegenerative diseases face challenges due to poor blood-brain barrier permeability, leading to ineffective delivery of autophagy-inducing agents, and existing autophagy-inducing compounds have limited selectivity and are associated with undesirable side effects.

Method used

Development of novel Beclin-1 derived peptides conjugated with a cell-penetrating peptide (CPP) and an endosomal escape domain, enhancing cellular uptake and blood-brain barrier permeability to induce autophagy effectively.

Benefits of technology

The conjugated peptides demonstrate increased autophagy induction in both in vitro and in vivo models, showing potential for treating neurodegenerative diseases by effectively crossing the blood-brain barrier and targeting the central nervous system.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000002_0002
    Figure IMGF000002_0002
  • Figure IMGF000019_0001
    Figure IMGF000019_0001
Patent Text Reader

Abstract

The present disclosure relates to peptides capable of inducing autophagy and the use of such peptides in the treatment of diseases and conditions associated with impaired autophagy.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] AUTOPHAGY-INDUCING PEPTIDES

[0002] Field of the Disclosure

[0003] The present disclosure relates to peptides capable of inducing autophagy and the use of such peptides in the treatment of diseases and conditions associated with impaired autophagy.

[0004] Cross-reference to related

[0005] This application claims priority to Australian application no. AU 2023901720 filed 31 May 2023.

[0006] The entire contents are incorporated herein by reference.

[0007] Reference to

[0008] The entire content of the electronic submission of the sequence listing is incorporated by reference in its entirety for all purposes.

[0009] Background

[0010] Autophagy is an evolutionarily conserved intracellular degradation system that plays a vital role in maintaining homeostasis in all eukaryotic cells. Autophagy has also been shown to play an essential role in other physiological processes, such as cell differentiation and development, tissue remodelling and innate immunity. Autophagy is a multi-step and dynamic process that occurs at a basal level in most tissues. The autophagy process, referred to as "autophagy flux", involves: autophagy initiation by the formation of a pre- autophagosomal structure (PAS); fusion of membranes of PAS to form double-membrane vesicles called autophagosomes that envelop cargo; trafficking and fusion of autophagosomes with lysosomes and forming autolysosomes; and degradation of cargo and recycling of generated macromolecules to the cytoplasm for reuse.

[0011] Impairment of autophagy has been implicated in a myriad of human conditions and diseases, including cancer, immune system disorders, muscular diseases, metabolic disorders, inflammation, age-related macular degeneration, stroke and neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tauopathies and Amyotrophic Lateral Sclerosis. Subsequently, the ability of autophagic processes to deliver cytoplasmic content to lysosomes for degradation has been identified as an attractive therapeutic target for a range of debilitating diseases. In particular, the pharmacological upregulation of autophagy to promote clearance of neurotoxic protein aggregates, a common clinical feature of neurodegenerative diseases, has been recognised as a viable therapeutic avenue for managing these diseases.

[0012] To date, no selective, effective, and safe autophagy-inducing agents have been identified. Most agents used to induce autophagy, such as rapamycin and tamoxifen, are small molecule compounds with multiple targets and many undesirable side effects.

[0013] The Beclin-1 protein is regarded to be central to autophagic processes. It is the smallestsubunit of a class III phosphatidylinositol 3-kinase (PI3K) complex, involved in both the early (i.e., autophagosome formation) and late (i.e., autolysosome formation) steps of the autophagy pathway (McKnight et al., 2013, Curr Pathobiol Reports 1 :231-238). Moreover, a large number of proteins modulate autophagy activity through interactions with Beclinl . Beclinl deficiency has been shown to impair autophagy (Yue et al., 2003, PNAS 100:15077- 15082), while its overexpression stimulates autophagy and is protective in cellular and animal models of different diseases.

[0014] The evolutionarily conserved domain (ECD) of Beclin-1 binds to the intracellular mammalian Golgi-associated plant pathogenesis-related protein 1 (GAPR-1), a negative regulator of autophagy. Domain-minimised peptide analogues of ECD have recently been shown to have autophagy-inducing efficacy at high concentrations (10-20 pM) by binding to GAPR-1 , thus, releasing endogenous Beclin- 1 to participate in autophagy (Shoji-Kawata et al., 2013, Nature 494:201-206). The Beclin-1 peptide was conjugated to the HIVtransactivator of transcription (TAT) peptide to enhance its cellular uptake. Although TAT- Beclin-1 peptide induced autophagy in the central nervous system (CNS) in neonatal mice following intraperitoneal injection, it failed to induce autophagy in the CNS of adult mice (Shoji- Kawata et al., 2013, Nature 494:201-206), indicating a lack of blood-brain barrier permeability of the peptide.

[0015] The blood-brain barrier presents a semi-permeable barrier between the circulatory system and the central nervous system (CNS), by which the microvasculature of the CNS tightly regulates the movement of molecules, ions, and cells between the blood and the CNS. This allows endothelial cells of the blood-brain barrier to regulate CNS homeostasis, which is critical for proper neuronal function, as well as to protect the CNS from toxins, pathogens, inflammation, injury, and disease. Similarly, the blood-aqueous humor barrier (also known as the blood-aqueous barrier) and the blood- retinal barrier (together, the blood-ocular barriers) present a physical semi-permeable barrier between intraocular tissues and the surrounding blood vessels. The restrictive nature of the blood- brain barrier and the blood-ocular barriers present a significant obstacle fordrug delivery. For example, the majority of drugs developed for the treatment of neurological and neuromuscular disorders are limited in efficacy by their poor penetration of the blood-brain barrier.

[0016] Direct injection of drugs into the brain or spinal column, thus bypassing the blood-brain barrier is not only highly invasive and expensive, but is ineffective due to the small volume of drug that can be administered and poor diffusion of the drug from the injection site. Disrupting the blood-brain barrier, for example, by infusing hyperosmolar solutions to remove water from capillary endothelial cells, thereby shrinking them to open gaps, or the use of bradykinin receptor agonists to loosen tight junctions, is also of limited effectiveness and suffers from the drawback that blood-brain barrier disruption weakens the barrier and allows the non-specific entry of other, potentially toxic molecules.

[0017] Significant efforts have been made to generate methods to improve the ability of drugs to penetrate the blood-brain barrier and the blood-ocular barriers, including the use of molecules such as peptides to 'shuttle' or carry drugs across these barriers. Peptides offer significant advantages as a vehicle for the delivery of agents across the blood-brain barrier, including small size, low toxicity, targeting specificity and their ability to carry large molecular weight agents. However, to date the efficiency of delivery of drugs such as antisense oligonucleotides across the blood-brain barrier when conjugated to peptide shuttles is compromised, and hence efficacy reduced, as such complexes typically accumulate in endosomes or lysosomes.

[0018] The formation and accumulation of toxic misfolded protein aggregates within neurons is a unifying clinical feature and a main pathological hallmark of many neurodegenerative diseases. Current therapeutic approaches include small molecule inhibitors and monoclonal antibodies that bind and clear aggregates. Despite promising results in preclinical studies, they have largely failed to show significant benefits in clinical trials. The development of effective protein aggregate-targeting therapies has been challenging due to the complex nature of protein aggregation and the conformational state that aggregates adopt. These make them unrecognisable by neutralising antibodies or small molecule inhibitors. Significantly, their poor blood-brain barrier (BBB) permeability limit the central nervous system (CNS) bioavailability.

[0019] There remains a need forthe development of improved peptide shuttles to facilitate the targeted delivery of active agents to the CNS via the blood-brain barrier and to the eye via the blood-ocular barriers, including agents to increase autophagy activity and thereby provide therapeutic benefit in the treatment of a range of neurodegenerative and ocular diseases.

[0020] Summary of the Disclosure

[0021] As described and exemplified herein, the inventors have designed, synthesised, and characterised a series of novel peptide derivatives of the evolutionarily conserved domain (ECD) of Beclin-1 (referred to herein as Beclin-1 derived peptides). To deliver the peptides into the cells and across the BBB into the CNS, they were conjugated to a BBB cell-penetrating peptide (CPP) which is described in the inventors' International Patent Application No. PCT / AU2021 / 051255, the disclosure of which is incorporated herein in its entirety. The resulting conjugated peptides display enhanced cellular uptake, cytosolic bioavailability and blood-brain-barrier permeability.

[0022] In a first aspect, the disclosure provides an isolated peptide comprising:

[0023] (i) at least one cell penetrating peptide (CPP) sequence comprising

[0024] (a) an endosomal escape domain (EED) sequence; and

[0025] (b) an apolipoprotein A (ApoE) sequence; and

[0026] (ii) at least one sequence comprising up to about 30 contiguous amino acid residues derived from an evolutionary conserved domain (ECD) of a Beclin-1 derived peptide (BCN) or derivative thereof.

[0027] In a preferred embodiment, the CPP is conjugated or linked to the N-terminus of the Beclin-1 derived peptide.

[0028] In one example, the Beclin-1 derived peptide or analogue comprises a sequence within amino acid residues 263 to 289 of the human Beclin-1 sequence. In a further example, the Beclin-1 sequence comprises the sequence set forth in MEGSKTSNNSTMQVSFVCQRCSQPLKLDTSFKILDRVTIQELTAPLLTTAQAKPGETQEEETNSGEEPF IETPRQDGVSRRFIPPARMMSTESANSFTLIGEASDGGTMENLSRRLKVTGDLFDIMSGQTDVDHPLC EECTDTLLDQLDTQLNVTENECQNYKRCLEILEQMNEDDSEQLQMELKELALEEERLIQELEDVEKNRK IVAENLEKVQAEAERLDQEEAQYQREYSEFKRQQLELDDELKSVENQMRYAQTQLDKLKKTNVFNATF HIWHSGQFGTINNFRLGRLPSVPVEWNEINAAWGQTVLLLHALANKMGLKFQRYRLVPYGNHSYLESL TDKSKELPLYCSGGLRFFWDNKFDHAMVAFLDCVQQFKEEVEKGETRFCLPYRMDVEKGKIEDTGGS GGSYSIKTQFNSEEQWTKALKFMLTNLKWGLAWVSSQFYNK (SEQ ID NO:1).

[0029] In one example, the Beclin-1 derived peptide or analogue comprises the sequence HIWHSGQFGT (SEQ ID NO:2).

[0030] In one example, the endosomal escape domain (EED) sequence comprises a pH-dependent endosomal membrane disrupting moiety. In another example, the EED peptide comprises an N-terminal fragment of the influenza virus hemagglutinin subunit HA2, a GALA peptide or a nuclear localisation sequence. In a further example, the HA2 peptide comprises the amino acid sequence set forth in GLFHAIAHFIHGGWH (SEQ ID NO:9), a derivative thereof, or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto.

[0031] In one example, the EED comprises a peptide fragment of an IZUMO protein (e.g., human IZUMO1). In one example, the EED comprises or consists of the amino acid sequence set forth in HLQKETFATYVARFQKEAY (SEQ ID NO: 26).

[0032] In one example, the ApoE sequence is a peptide fragment comprising (or consisting of) the sequence set forth in LRKLRKRLLR (SEQ ID NO:7). In another example, the ApoE sequence comprises (or consists of) the sequence set forth in LRVRLASHLRKLRKRLLR (SEQ ID NO:8).

[0033] In one example, the peptide further comprises one or more active agents. The active agent may be for example, a therapeutic agent, a diagnostic agent, a detection agent or an agent for imaging biological tissue. Suitable active agents include nucleic acid-based constructs such as antisense oligonucleotides and protein-, polypeptide- or peptide-based moieties. In one example, the active agent is conjugated or linked to the N-terminus of the at least one CPP. In another example, the active agent is conjugated or linked to the C-terminus of the at least one Beclin-1 derived peptide.

[0034] In another example, the at least one CPP is acetylated at the N-terminus, or myristoylated at the N-terminus.

[0035] In another example, the peptide is acetylated at the N-terminus. In another example, the peptide is amidated at the C-terminus. In one example, the peptide is acetylated at the N-terminus and amidated at the C-terminus.

[0036] In one example, the peptide comprises from N to C-terminus (i) the at least one CPP peptide followed by (ii) the at least one BCN peptide or derivative thereof.

[0037] In a further example the CPP and BCN peptide is linked by a linker sequence. In another example, the linker is a diglycine linker (-GG-) or a GS linker. In another example, the CPP and BCN peptide are linked by an mPEG spacer, such as an (mPEG)2 spacer (i.e., -mPEG-mPEG-).

[0038] In another example, the EED and ApoE sequences are linked by a linker sequence. In another example, the linker is a diglycine linker (-GG-) or a GS linker. In another example, the EED and ApoE peptide are linked by an mPEG spacer, such as an (mPEG)2 spacer (i.e., -mPEG-mPEG-).

[0039] In one example, the CPP comprises the sequence GLFHAIAHFIHGGWH-GG-LRKLRKRLLR (SEQ ID NO:11).

[0040] In on example, the BCN peptide or derivative comprises or consists of a sequence selected from the group consisting of (i) TNVFNATFHIWHSGQFGT (BCN1 ; SEQ ID NO:5), (ii) KLKKTNVFNATFHIWHSGQFGT (BCN2; SEQ ID NO:6), (Hi) TNVFNATFHIWHSGQFGTINNFR (BCN3; SEQ ID NO:4) or (iv) HIWHSGQFGTINNFR (BCN4: SEQ ID NO:3).

[0041] In one example, the peptide comprises (or consists of) a sequence selected from the group consisting of (i) GLFHAIAHFIHGGWH-GG-LRKLRKRLLR-GG-HIWHSGQFGTINNFR (SEQ ID NO:13), GLFHAIAHFIHGGWH-GG-LRKLRKRLLR-GG-TNVFNATFHIWHSGQFGTINNFR (SEQ ID NO:14), GLFHAIAHFIHGGWH-GG-LRKLRKRLLR-GG-TNVFNATFHIWHSGQFGT (SEQ ID NO:15) and GLFHAIAHFIHGGWH-GG-LRKLRKRLLR-GG-KLKKTNVFNATFHIWHSGQFGT (SEQ ID NO:16). In one example, the peptide comprises (or consists of) a sequence of HLQKETFATYVARFQKEAY-GG-LRKLRKRLLR-GG-HIWHSGQFGTINNFR (SEQ ID NO: 27) or GLFHAIAHFIHGGWH-GG-LRVRLASHLRKLRKRLLR-GG-HIWHSGQFGTINNFR (SEQ ID NO: 28).

[0042] In one example, the peptide comprises (or consists of) a sequence of GLFHAIAHFIHGGWH- GG-LRVRLASHLRKLRKRLLR-GG-HIWHSGQFGTINNFR (SEQ ID NO: 28).

[0043] In one example, the peptide comprises (or consists of) the amino acid sequence of SEQ ID NO: 11 conjugated to the amino acid sequence of SEQ ID NO: 3 via a -mPEG-mPEG- spacer, i.e., GLFHAIAHFIHGGWH-GG-LRKLRKRLLR-mPEG-mPEG-HlWHSGQFGTINNFR.

[0044] In a particular example, the peptide comprises (or consists of) the sequence set forth in GLFHAIAHFIHGGWH-GG-LRKLRKRLLR-GG-HIWHSGQFGTINNFR (SEQ ID NO:13).

[0045] In a particular example, the peptide comprises (or consists of) the sequence set forth in Ac- GLFHAIAHFIHGGWH-GG-LRKLRKRLLR-GG-HIWHSGQFGTINNFR-NH2 (SEQ ID NO:25).

[0046] In one embodiment, the peptide is provided as a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient.

[0047] In a second aspect, the present disclosure provides an isolated peptide comprising:

[0048] (i) a sequence comprising an endosomal escape domain;

[0049] (ii) a sequence comprising the amino acid sequence set forth in SEQ ID NO:7 or 8 or a sequence having at least or about 90% sequence identity thereto; and

[0050] (iii) a sequence of up to about 30 contiguous amino acid residues of the Beclin-1 sequence set forth in SEQ ID NO:1 , wherein the contiguous amino acid residues comprise or consist of residues between positions 263-289 of SEQ ID NO:1.

[0051] In one example, the peptide comprises, from N-terminus to C-terminus, sequence (i), sequence (ii), and sequence (iii). In one example, a linker separates sequence (i) and sequence (ii) and / or a linker separates sequence (ii) and sequence (iii). In particular examples, the linker comprises a diglycine (GG) linker.

[0052] In particular embodiments, the sequence (iii) of the second aspect comprises the amino acid sequence of SEQ ID NO:2 or a sequence having at least or about 90% sequence identity thereto. In another embodiment, sequence (iii) comprises or consists of the amino acid sequence set forth in SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6, or a sequence having at least or about 90% sequence identity thereto. In an example, sequence (iii) comprises or consists of the amino acid sequence set forth in SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6. In particular exemplary embodiments, sequence (iii) of the peptide comprises or consists of the amino acid sequence set forth in SEQ ID NO:3 or SEQ ID NO:4.

[0053] In one example, the endosomal escape domain comprises or consists of the amino acid sequence set forth in SEQ ID NO:9 or a sequence having at least or about 90% sequence identity thereto.

[0054] In exemplary embodiments, sequence (ii) of the second aspect comprises or consists of the amino acid sequence set forth in SEQ ID NO:7 (ApoE).

[0055] In further examples according to any aspect, the peptide comprises or consists of the sequence set forth in SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 or SEQ ID NO:16, or a sequence having at least or about 90% sequence identity thereto.

[0056] In particular exemplary embodiments, the peptide comprises or consists of the sequence set forth in SEQ ID NO:13 or SEQ ID NO:14.

[0057] In a further example, the BCN peptide does not comprise or consist of amino acid substitutions H275E, S279D and Q281 E relative to the sequence set forth in SEQ ID NO:1 .

[0058] In a third aspect, the present disclosure provides an isolated peptide comprising a sequence of up to about 30 contiguous amino acid residues of the Beclin-1 sequence set forth in SEQ ID NO:1 , wherein the contiguous amino acid residues comprise or consist of residues between positions 263-289 of SEQ ID NO:1 , wherein the peptide does not contain the substitutions H275E, S279D and Q281 E, and wherein the peptide is capable of inducing autophagy in a cell.

[0059] In particular embodiments according to any aspect, the contiguous amino acid residues comprise or consist of residues at positions 275-284 of SEQ ID NO:1. The contiguous amino acid residues may comprise or consist of residues at positions 275-289 of SEQ ID NO:1. The contiguous amino acid residues may comprise or consist of residues at positions 267-289 of SEQ ID NO:1. The contiguous amino acid residues may comprise or consist of residues at positions 267-284 of SEQ ID NO:1 . The contiguous amino acid residues may comprise or consist of residues at positions 263-284 of SEQ ID NO:1.

[0060] In a fourth aspect, the present disclosure provides an isolated peptide comprising or consisting of the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6. In particular exemplary embodiments, the peptide comprises orconsists ofthe amino acid sequence set forth in SEQ ID NO:3 orSEQ ID NO:4.

[0061] In another embodiment, optionally the peptide of the third or fourth aspects is linked to a cellpenetrating peptide (CPP) sequence. The cell-penetrating peptide sequence may comprise a fusion peptide comprising (i) an endosomal escape domain, and (ii) a peptide sequence comprising the amino acid sequence set forth in SEQ ID NOT or 8 or a sequence having at least or about 90% sequence identity thereto. In exemplary embodiments, the cell-penetrating peptide sequence comprises or consists of the sequence set forth in SEQ ID NO:10, SEQ ID NO:11 or SEQ ID NO:12.

[0062] In a fifth aspect, also provided are fusion peptides comprising a BCN peptide as described herein and a cell-penetrating peptide. In exemplary embodiments, the fusion peptide comprises or consists of the sequence set forth in SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 or SEQ ID NO:16, or a sequence having at least or about 90% sequence identity thereto. In particular exemplary embodiments, the fusion peptide comprises or consists of the sequence set forth in SEQ ID NO:13 or SEQ ID NO:14.

[0063] In a further exemplary embodiment, the fusion peptide further comprises an active agent.

[0064] In a sixth aspect, the present disclosure vectors comprising a nucleotide sequence(s) encoding a peptide disclosed herein, in particular a peptide of the first, second, third, fourth or fifth aspect.

[0065] In a seventh aspect, there is provided a cell transfected with a peptide of the disclosure, in particular a peptide according to the first, second, third fourth or fifth aspect.

[0066] In an eighth aspect, the present disclosure provides a method for inducing autophagy in a cell, comprising exposing the cell to a peptide (or fusion peptide) of the disclosure, in particular a peptide according to the first or second aspect. In one example, the cell is a cell of the central nervous system. In another example the cell is a motor neuron.

[0067] Without wishing to be bound by theory, although the exemplified embodiments are described by reference to the NSC-34 cell line (a motor neuron cell line), it is understood that the BCN peptides, and hence the isolated peptides described herein are capable of being expressed in other cell types including neuronal cells (He M et al., (2016) PNAS vol 113(40): 1 1324), Hela cells (Shoji-Kawata S et al., (2013) 494(7436):201), liver cells (Soria LR et al., (2021) EMBO Molecular Medicine 13: e13158) and card io myocytes (Forte M et al., (2023) Autophagy vol 19(4):1087).

[0068] In a ninth aspect, the disclosure provides a method for inducing autophagy in one or more cells in a subject, comprising administering to the subject a peptide of the disclosure, in particular a peptide according to the first or second aspect. In one example, the one or more cells are cells of the central nervous system. In a further example, the cells are motor neurons. In one example, the subject has a disease or condition associated with impaired autophagy in one or more cells, for example cells of the central nervous system.

[0069] In one example, the disease or condition is a neurodegenerative disease or condition. In a further example, the neurodegenerative disease or condition is selected from Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, amyotrophic lateral sclerosis and a tauopathy.

[0070] In a tenth aspect, the disclosure provides a method for treating or preventing a condition associated with impaired autophagy, comprising administering to a subject in need thereof a peptide of the present disclosure, in particular a peptide according to the first or second aspect.

[0071] In an eleventh aspect, the disclosure provides a method for treating or preventing a neurodegenerative disease, comprising administering to a subject in need thereof a peptide of the present disclosure, in particular a peptide according to the first or second aspect.

[0072] In a twelfth aspect, the disclosure provides a method for treating or preventing a neurodegenerative disease caused by the accumulation of protein aggregates within neurons of a subject, the method comprising administering to the subject a peptide of the disclosure, in particular a peptide according to the first or second aspect to the subject.

[0073] In a thirteenth aspect, the disclosure provides use of a peptide as described herein, in particular a peptide according to the first or second aspect, in the manufacture of a medicament for treating a neurodegenerative disease or condition in a subject, including a neurodegenerative condition caused by the accumulation of protein aggregates within neurons.

[0074] In a fourteenth aspect, the disclosure provides a method of treating an oculardisorder, preferably glaucoma, comprising administering to a subject in need thereof a peptide of the present disclosure, in particular a peptide according to the first or second aspect.

[0075] In one example, the neurodegenerative disease is selected from Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, amyotrophic lateral sclerosis (ALS) and a tauopathy.

[0076] Brief Description of the Drawings

[0077] Aspects and embodiments of the present disclosure are described herein, by way of non-limiting example only, with reference to the following drawings.

[0078] Figure 1. Sequences and predicted structures of peptides derived from the evolutionarily conserved domain (ECD) of Beclin 1. The x-ray crystal structure of ECD (PDB ID: 4ddp) was used to guide the design of the BCN1-BCN4 peptides. ICM-browser (MolSoft v.3.9, San Diego, 2019) was used to create the structure of the peptides.

[0079] Figure 2. Schematic synthesis of cyclic analogues of BCN1 peptide. (A.i) Linear peptide dissolved in water (1.5 mg / ml) and 2,2'-dipyridyldisulfide (DPDS) (5 eq.) in methanol was added dropwise to the stirring solution of peptide. (B.i) Formation of thioether bridge using dibromo-o-xylene linker (1.5 eq) dissolved in acetonitrile (ACN) added to the peptide solution (1 mM in ACN / H2O). (C) On-resin formation of lactam bridge and its cleavage from solid-support, (i) 20% hydrazine in DMF, (ii) HATU:HoAt:DIEA (4:2:8), (iii) TFA:H20:DoDT:TIPS (94:2.5:2.5:1 v / v).

[0080] Figure 3. The effect of BCN peptides on autophagy flux. NSC-34 cells were transfected with mCherry- EGFP-LC3 reporter construct and 24 h later, treated with 5 pM of BCN peptides or 0.5 pg / mL of rapamycin (Rapa) for 24 h and 400 nM of bafilomycin A1 (BafA1) for 6 h. Cells were stained with Hoechst, fixed, imaged with confocal microscopy and the number of autophagosomes and autolysosomes per cell was counted. (A) Representative confocal images of autolysosomes, (B) quantification of autophagosomes as a % of total autophagic vesicles in the untreated group, and (C) autophagy flux (autolysosomes to autophagosomes ratio) as a % ofthe untreated group. Comparisons between treated and untreated were made using a one-way ANOVA with Dunnett’s, and further comparisons between CPP-conjugated peptides and unconjugated peptides were made using Sidak’s post-hoc test. Values represent mean + SEM relative to untreated control from at least 3 independent experiments (except for BafA1 , which is from 1 independent experiment), *p<0.05, **p<0.01 , ***p<0.001 . Scale bar = 20 pm.

[0081] Figure 4. The concentration-dependent effect of CPP-BCN4 and TAT-BECN1 and serum starvation on autophagy flux. NSC-34 cells were transfected with mCherry-EGFP-LC3 reporter construct and 24 h later treated with 0.1 , 1 .25, 2.5, 5, 10, 20 and 40 pM CPP-BCN4, 5 and 20 pM TAT-BECN1 or starved by culturing in cell media lacking in serum for 24 h. In addition, untreated cells or cells treated with 20 pM CPP-BCN4 were co-treated with 0.4 pM bafilomycinAI (BafA1) for 6 h. Cells were stained with Hoechst, fixed, and imaged with confocal microscopy, and the number of autophagosomes and autolysosomes per cell were counted. (A) Representative confocal images of autolysosomes and autophagosomes. Quantification of (B) autolysosomes and autophagosomes as a % of total autophagic vesicles in the untreated group, and (C) autophagy flux (autolysosomes to autophagosomes ratio) as a % of the untreated group. Comparisons were made using a one-way ANOVA with Dunnett’s post-hoc test. Values represent mean + SEM relative to untreated control, from at least 3 independent experiments, *p<0.05, **p<0.01 , ***p<0.001 . Scale bar =20 pm.

[0082] Figure 5. The effect of CPP-BCN4 on autophagy proteins. NSC-34 cells were treated with 5, 10 and 20 pM CPP-BCN4, and 24 h later, cells were harvested. The supernatant fraction was extracted with Triton X-100. (A) Representative Western blot and densitometric analysis of (B) LC3-II protein and (C) p62 protein normalised to -actin. The pellet fraction was extracted with SDS and Urea. (D) Representative Western blot and densitometric analysis of (E) p62 protein normalised to total protein. Data were normalised to untreated cells (expressed as 100%), and comparisons were made using a one-way ANOVA with Dunnett’s post-hoc test. Values represent mean + SEM relative to untreated control from at least 8 independent experiments. *** p<0.001 .

[0083] Figure 6. The effect of CPP-BCN4 on C9orf72 poly-GR puncta. NSC-34 cells were transiently transfected with EGFP-101x GR and treated with 10 pM of CPP-BCN4 for 48 h. Cells were stained with Hoechst, fixed, and imaged with confocal microscopy. (A) Representative confocal images and (B) quantification of the number of cells containing EGFP-poly-GR puncta from >100 transfected cells. Comparisons were made to untreated cells using an unpaired t-test. Values represent + SEM from at least 3 independent experiments. * p<0.05. Scale bar = 20 pm.

[0084] Figure 7. Cell uptake and intracellular localisation of Cy5-labelled BCN peptides. NSC-34 cells were treated with 5 pM of (A) Cy5-BCN4 and (B) Cy5-CPP-BCN4. Live cells were stained with Hoechst and imaged 30 min, 1 h, 2 h and 3 h post- treatment with confocal microscopy. Scale bar = 20 pm.

[0085] Figure 8. Effect of CPP-BCN4 on cell viability and proteolytic stability in vitro. (A) NSC-34 cells were treated for 24 h with 0.01 , 0.1 , 1 , 10, 20, 30, 40, 50 and 100 pM of CPP-BCN4. Subsequently, cell viability was assessed using the MTS by measuring the absorbance at 490 nm. Comparisons were made using a one-way ANOVA with Dunnett’s post-hoc test from at least 3 independent experiments. Data represent mean + SEM relative to untreated control, * p<0.05, ** p<0.01 , *** p<0.001 , **** p<0.0001. (B) The proteolytic stability of CPP-BCN4 in human serum. CPP-BCN4 (50 nmol) was incubated in 50% of human serum for 10 min, 30 min, 1 h, 4 h and 24 h at 37°C. Subsequently, the percentage of intact peptide remaining at each timepoint was analysed in triplicate with analytical RP- HPLC.

[0086] Figure 9. Effect of 2 weeks CPP-BCN4 treatment via ICV on the level of autophagy in the spinal MNs. CAG-RFP-GFP-LC3 mice at P60 were administered continuously with saline or 10 pg / day of CPP- BCN4 via ICV infusion over 2 weeks. Mice were perfused, and their lumbar spinal cord was collected. MNs were labelled with NeuN and imaged with confocal microscopy. The number of autophagosomes and autolysosomes from at least 25 MNs per mouse were automatically quantified with the Imaris software. (A) Representative confocal images of autolysosomes and autophagosomes. Quantification of (B) autolysosomes, autophagosomes, and (C) autophagy flux or the ratio of autolysosomes to autophagosomes as a % of the saline group and (D) volume of autophagosomes and auto lysosomes. Comparisons were made using an unpaired t-test. Values represent mean + SEM relative to saline from 5-6 mice. Scale bar = 20 pm.

[0087] Figure 10. Effect of 3 weeks CPP-BCN4 treatment via IV on the level of autophagy in the spinal MNs. CAG-RFP-GFP-LC3 mice at P60 were administered with saline, 10 mg / kg ofCPP-Scram BCN4 orCPP- BCN4 via 6 times IV injections over 3 weeks. Mice were perfused, and their lumbar spinal cord was collected. MNs were labelled with NeuN and imaged with confocal microscopy. The number of autophagosomes and autolysosomes from at least 25 MNs per mouse were automatically quantified with the Imaris software. (A) Representative confocal images of autolysosomes and autophagosomes. Quantification of (B) autolysosomes, autophagosomes, and (C) autophagy flux or the ratio of autolysosomes to autophagosomes as a % of the saline group and (D) volume of autophagosomes and autolysosomes. Comparisons were made using a one-way ANOVA with Dunnett’s post-hoc test or an unpaired t-test. Values represent mean + SEM relative to saline from 5-6 mice. Scale bar = 20 pm.

[0088] Figure 11. Effect of CPP-BCN4 on lysosomes in the spinal MNs. CAG-RFP-EGFP-LC3 mice at P60 were administered saline or CPP-BCN4 continuously at 10 pg / day for 2 weeks via ICV infusion, ortwice a week at 10 mg / kg for 3 weeks via IV injections. Mice were perfused, and their lumbar spinal cord was collected. MNs were labelled with NeuN and LAMP1 and imaged with confocal microscopy. The number of autophagosomes, autolysosomes and lysosomes from at least 25 MNs per mouse were automatically quantified with the Imaris software. (A) Representative confocal images, and quantification of (B) lysosomes over volume of MNs and (C) lysosomes colocalised with autophagosomes and autolysosomes as a % of total autophagic vesicles in the same group. Comparisons were made using an unpaired t-test. Values represent mean + SEM relative to saline from 3-6 mice. Scale bar = 20 pm.

[0089] Figure 12. Alanine transaminase (ALT) activity and levels of immunoglobulin G (IgG) in serum of mice treated with CPP-BCN4. CAG-RFP-EGFP-LC3 mice were ICV infused continuously for 2 weeks at 10 pg / day or IV injected twice a week for3 weeks at 10 mg / kg. (A) The activity of ALT and (B)the concentration of IgG in serum was analysed. Comparisons were made using a one-way ANOVA with Dunnett’s post-hoc test. Data represent mean + SEM relative to saline treated group from at least 5 mice.

[0090] Figure 13. Effect of CPP-BCN peptides on insoluble superoxide dismutase 1 (SOD1) proteins. NSC-34 cells were transiently transfected with either WT SOD1-EGFP or A4V SOD1-EGFP for 1 h. Subsequently, cells were treated with 5 and 10 pM of CPP-BCN3, CPP-BCN4 or BCN3-CPP for 24 h. Following treatment, cells were harvested, and the pellet fraction enriched with insoluble proteins was extracted with SDS and Urea. A representative Western blot, along with densitometric analysis of EGFP protein normalised to total protein, was conducted. Comparisons were made using a one-way ANOVA with Dunnett’s post-hoc test. Values represent mean + SEM relative to untreated from at least 3 independent experiments. * p<0.05, ** p<0.01 , *** p<0.001 , **** p<0.0001 .

[0091] Figure 14. Effect of CPP-BCN4 on caspase-3 activation. NSC-34 cells were transiently transfected with either WT SOD1-EGFP or A4V SOD1-EGFP. Cells were treated 1 h post-transfection with 10 pM of CPP-BCN4 or CPP-Scram BCN4 for 48 h, or alternatively, with 1 pM of Staurosporine (STS) for 2 h. Subsequently, cells were fixed, stained with cleaved caspase-3 and Hoechst, and imaged with confocal microscopy. Representative confocal images were acquired, and quantification of the number of cells containing cleaved caspase-3 from 100 transfected cells was performed. Comparisons were made using a one-way ANOVA with Dunnett’s post-hoc test. Values represent + SEM from at least 3 independent experiments. * p<0.05, ** p<0.01 , *** p<0.001 , **** p<0.0001 . Scale bar = 10 pm.

[0092] Figure 15. Effect of intravenous (IV) injection of CPP-BCN4 on the (A) survival and (B) efficacy clinical biomarker (neurofilament light chain (NfL)) in an ALS mouse model expressing SOD1 G93A. SOD1 G93A mice, starting at P45, were IV injected once weekly for a duration of 10 weeks, with either 10 mg / kg of CPP-BCN4 or CPP-Scram BCN4. Kaplan-Meier survival curves were generated and comparison between the two treatment groups was made using Log-rack test or unpaired t-test from 10-11 mice. * p<0.05. **<0.01 .

[0093] Figure 16 shows the effect of BCN peptides on autophagy flux. NSC-34 cells were transfected with mCherry-EGFP-LC3 reporter construct and 24 h later, treated with 5 pM of BCN peptides for 24 h. Autophagy flux (autolysosomes to autophagosomes ratio) relative to untreated cells. Values represent + SEM from at least 3 independent experiments.

[0094] Detailed Description

[0095] Definitions

[0096] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the disclosure belongs. All patents, patent applications, published applications and publications, databases, websites and other published materials referred to throughout the entire disclosure, unless noted otherwise, are incorporated by reference in their entirety. In the event that there is a plurality of definitions for terms, those in this section prevail. Where reference is made to a URL or other such identifier or address, it understood that such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet. Reference to the identifier evidences the availability and public dissemination of such information.

[0097] The articles “a” and “an” are used herein to referto one orto more than one ( / .e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0098] In the context of this specification, the term "about," is understood to referto a range of numbers that a person of skill in the art would consider equivalent to the recited value in the context of achieving the same function or result.

[0099] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

[0100] The term "optionally" is used herein to mean that the subsequently described feature may or may not be present or that the subsequently described event or circumstance may or may not occur. Hence the specification will be understood to include and encompass embodiments in which the feature is present and embodiments in which the feature is not present, and embodiments in which the event or circumstance occurs as well as embodiments in which it does not.

[0101] The term “peptide” means a polymer made up of amino acids linked together by peptide bonds. The term “polypeptide” may also be used to refer to such a polymer although in some instances a polypeptide may be longer (i.e. composed of more amino acid residues) than a peptide. Typically, the term peptide is used to define a sequence of amino acids of up to about 70 amino acids, although the terms "peptide" and "polypeptide" may be used interchangeably herein.

[0102] The term “autolysosome” refers to a lysosome that enables the digestion of injured portions of the cell in which it is located.

[0103] The term “autophagosome: refers to a double membrane bound vesicle that encloses cellular constituents and fuses with lysosomes which digest these cellular constituents during autophagy.

[0104] The term “autophagy flux” as used herein refers to a measure of autophagic degradation activity, namely the rate of autophagic degradation.

[0105] As used herein, "isolated" with reference to a polynucleotide or polypeptide means that the polynucleotide or polypeptide is substantially free of cellular material or other contaminating proteins from the cells from which the polynucleotide or polypeptide is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized.

[0106] The term “fusion peptide” as used herein relates to a peptide comprising two or more heterologous regions or domains not found operably linked in nature. Optionally a linker sequence may connect or join the two or more heterologous regions or domains.

[0107] As used herein the term "endosomal escape domain" means a peptide sequence, or an agent comprising a peptide sequence, that facilitates, induces or otherwise allows the release of a peptide to which it is conjugated, linked or otherwise joined or attached from endosomal vesicles. Thus, in the context of fusion peptides of the present disclosure the endosomal escape domain represents one heterologous region or domain of the fusion peptide.

[0108] A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. Conservative amino acid substitution also includes groupings based on side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. For example, it is reasonable to expect that replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the properties of the resulting variant peptide. Whether an amino acid change results in a functional peptide can readily be determined by assaying its activity.

[0109] As used herein the terms "treating", "treatment", “preventing”, “prevention” and grammatical equivalents refer to any and all uses which remedy, prevent, retard or delay the establishment of an oculardisorder, a neurological disorder, neuromusculardisorder, or other disorder affecting the CNS, or otherwise prevent, hinder, retard, or reverse the progression of such a disorder. Thus the terms "treating" and “preventing” and the like are to be considered in their broadest context. For example, treatment does not necessarily imply that a patient is treated until total recovery. Where the disorder displays or a characterized by multiple symptoms, the treatment or prevention need not necessarily remedy, prevent, hinder, retard, or reverse all of said symptoms, but may prevent, hinder, retard, or reverse one or more of said symptoms.

[0110] As used herein the term "effective amount" includes within its meaning a non- toxic but sufficient amount or dose of an agent or compound to provide the desired effect. The exact amount or dose required will vary from subject to subject depending on factors such as the species being treated, the age, size, weight and general condition of the subject, the severity of the disease or condition being treated, the particular agent being administered and the mode of administration and so forth. Thus, it is not possible to specify an exact "effective amount". However, for any given case, an appropriate "effective amount" may be determined by one of ordinary skill in the art using only routine experimentation.

[0111] The term "subject" as used herein refers to mammals and includes humans, primates, livestock animals (e.g. sheep, pigs, cattle, horses, donkeys), laboratory test animals (e.g. mice, rabbits, rats, guinea pigs), performance and show animals (e.g. horses, livestock, dogs, cats), companion animals (e.g. dogs, cats) and captive wild animals. Preferably, the mammal is human ora laboratory test animal.

[0112] Even more preferably, the mammal is a human.

[0113] It will be appreciated that the above described terms and associated definitions are used for the purpose of explanation only and are not intended to be limiting. Table 1 Exemplary sequences

[0114] X = aminohexanoic acid

[0115] Autophagy induction

[0116] Current prior art approaches to targeting protein aggregates rely on the recognition of protein conformation and therefore depending on the conformational state that the misfolded protein adopts, recognition by small molecules or antibodies can be compromised resulting in ineffective removal of aggregates. Furthermore, most protein aggregates are found intracellularly and mAbs can only neutralise extracellular aggregates due to their poor cell membrane permeability hence leaving most of the intracellular aggregates unaffected.

[0117] In contrast to these prior art methods, the inventors have adopted an approach for clearing protein aggregates which is not dependent on the conformational structure of the misfolded protein aggregates. This approach relies on removal of intracellular protein aggregates through upregulation of intra-cellular protein degradation systems and more specifically autophagy, a process which removes large cytoplasmic aggregates and dysfunctional organelles. Unlike mAbs and small molecules, autophagy is not affected by the conformational state of the protein aggregates.

[0118] Most autophagy-inducing compounds are small molecules with poor BBB-permeability, no selectivity, and undesirable side-effects unrelated to autophagy. Genetic knock-down of Beclin-1 has been shown to decrease autophagy. However, the majority of cytosolic Beclin-1 is held in sequestration by golgi-associated plant pathogenesis related protein 1 (GAPR-1) thereby limiting its autophagy inducing activity. Additionally, the part of Beclin-1 that is associated with autophagy activity is not BBB permeable and requires significantly high concentrations (i.e. about 30-50 pM).

[0119] Beclin-1 -derived peptides, cell-penetrating peptides and fusion peptides

[0120] As described and exemplified herein, the inventors have designed, synthesised, and characterised a series of novel peptides (together referred to herein as "BCN peptides") derived from the evolutionarily conserved domain of Beclin-1 . Upregulation of the cell’s endogenous protein clearing system (known as autophagy) to remove protein aggregates can prevent accumulation, release and spread if protein aggregates throughout the CNS. By preventing or halting neuronal loss, this should halt the progression of aggregate-associated neurodegenerative disease.

[0121] The inventors have discovered that by conjugating the BCN peptides to a cell penetrating peptide, autophagy is significantly upregulated and protein aggregates can be cleared in vitro and in vivo in motor-neuron cells. This was evidenced in the accompanying examples described herein demonstrating prevention of motor neuron degeneration and the reduction of neurofilament light chain (NfL), a clinically relevant biomarker of neurodegeneration.

[0122] In the present examples, autophagy was determined by measuring the average number of autophagosomes to autolysosomes orthe ratio thereof, wherein an increase in the number or proportion of autolysosomes compared to autophagosomes indicates upregulation in autophagy.

[0123] As exemplified herein, when delivered to motor neurons in vitro and in vivo, the peptides described herein display a potent ability to increase autophagy flux.

[0124] The amino acid sequence of human Beclin-1 (Uniprot Accession No. A0A024R1X5) is set forth in SEQ ID NO:1 . The Beclin-1 -derived peptides the subject ofthe present disclosure comprise a stretch of contiguous amino acids corresponding to amino acids at positions 275-284 of the Beclin-1 sequence of SEQ ID NO:1 , as set forth in SEQ ID NO:2, optionally including one or more conservative amino acid substitutions.

[0125] In one embodiment, the Beclin-1 -derived peptide comprises or consists of the amino acid sequence set forth in SEQ ID NO:3 (corresponding to positions 275-289 of the Beclin-1 sequence of SEQ ID NO:1), or a sequence having at least or about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity therewith, optionally including one or more conservative amino acid substitutions. For the purpose of the present disclosure a peptide consisting of the sequence of SEQ ID NO:3 is termed "BCN4". In exemplary embodiments of the disclosure, the peptide does not contain substitutions at positions corresponding to H275E, S279D and Q281 E of SEQ ID NO:1.

[0126] In one embodiment, the Beclin-1 -derived peptide comprises or consists of the amino acid sequence set forth in SEQ ID NO:4 (corresponding to positions 275-289 of the Beclin-1 sequence of SEQ ID NO:1), or a sequence having at least or about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity therewith, optionally including one or more conservative amino acid substitutions. For the purpose of the present disclosure a peptide consisting of the sequence of SEQ ID NO:4 is termed "BCN3". In exemplary embodiments of the disclosure, the peptide does not contain substitutions at positions corresponding to H275E, S279D and Q281 E of SEQ ID NO:1.

[0127] In one embodiment, the Beclin-1-derived peptide comprises or consists of the amino acid sequence set forth in SEQ ID NO:5 (corresponding to positions 275-289 of the Beclin-1 sequence of SEQ ID NO:1), or a sequence having at least or about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity therewith, optionally including one or more conservative amino acid substitutions. For the purpose of the present disclosure a peptide consisting of the sequence of SEQ ID NO:5 is termed "BCN1". In exemplary embodiments ofthe disclosure, the peptide does not contain substitutions at positions corresponding to H275E, S279D and Q281 E of SEQ ID NO:1. In one embodiment, the Beclin-1 -derived peptide comprises or consists of the amino acid sequence set forth in SEQ ID NO:6 (corresponding to positions 275-289 of the Beclin-1 sequence of SEQ ID NO:1), or a sequence having at least or about 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity therewith, optionally including one or more conservative amino acid substitutions. For the purpose of the present disclosure a peptide consisting of the sequence of SEQ ID NO:6 is termed "BCN2". In exemplary embodiments of the disclosure, the peptide does not contain substitutions at positions corresponding to H275E, S279D and Q281 E of SEQ ID NO:1.

[0128] Embodiments of the disclosure contemplate derivatives of BCN peptide sequences disclosed herein. As used herein the term "derivative" is intended to encompass chemical modification to a peptide or one or more amino acid residues of a peptide, including chemical modification in vitro, for example by introducing a group in a side chain in one or more positions of a peptide, such as a nitro group in a tyrosine residue or iodine in a tyrosine residue, by conversion of a free carboxylic group to an ester group or to an amide group, by converting an amino group to an amide by acylation, by acylating a hydroxy group rendering an ester, by alkylation of a primary amine rendering a secondary amine, or linkage of a hydrophilic moiety to an amino acid side chain. Other derivatives may be obtained by oxidation or reduction of the side-chains of the amino acid residues in the peptide. Modification of an amino acid may also include derivation of an amino acid by the addition and / or removal of chemical groups to / from the amino acid, and may include substitution of an amino acid with an amino acid analog (such as a phosphorylated or glycosylated amino acid) or a non-naturally occurring amino acid such as a N-alkylated amino acid (e.g. N-methyl amino acid), D-amino acid, -amino acid or y-amino acid.

[0129] The inventors have demonstrated herein that the potency of the BCN peptides described above in inducing autophagy is increased when linked to a cell-penetrating peptide facilitating efficient penetration of cellular membranes to reach their cytosolic target. Furthermore, to improve therapeutic efficacy in the treatment of neurodegenerative diseases, it is important to facilitate the delivery of the BCN peptides across the blood-brain barrier to allow access to neuronal targets in the central nervous system. Therefore, to enhance cellular uptake and cytosolic bioavailability as well as blood-brain-barrier permeability, the inventors have generated fusion peptides comprising the BCN peptides described herein conjugated or linked to a cell-penetrating peptide (CPP) The cel I- penetrating peptide itself may be a fusion peptide comprised of two or more heterologous domains or peptide sequences.

[0130] The inventors tested orientations in which the CPP was N or C-terminal to the BCN sequence. As demonstrated in Figure 11 , both orientations demonstrated activity however the orientation in which the CPP was N-terminal to the BCN peptide showed higher activity. This also allowed for the CPP to have access to both the membrane and its cell surface receptor (i.e. LDL receptors) and for the BCN peptide to have access to its target (GAPR-1).

[0131] In particular embodiments, the cell-penetrating peptide comprises a fusion peptide comprising (i) a peptide sequence comprising a fragment of the apolipoprotein E (ApoE) polypeptide, comprising the amino acid sequence set forth in SEQ ID NO: 7 or SEQ ID NO:8, or a sequence having at least or about 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity therewith, optionally including one or more conservative amino acid substitutions; and (ii) an endosomal escape domain (EED). The endosomal escape domain may be linked to the N-terminal or C-terminal end of the peptide sequence of (i) and may be linked directly or indirectly thereto. In particular embodiments, the endosomal escape domain is linked to the N-terminal end of the peptide sequence of (i), being the ApoE peptide. In one example, the C-terminal end of the endosomal escape domain is linked to the N-terminal end of the peptide sequence of (i), being the ApoE peptide.

[0132] Components (i) and (ii) of the cell-penetrating peptide may be directly attached to one another or may be attached via one or more linkers or spacers. As used herein, the terms "linker" and "spacer” refer to any molecule or group of molecules that binds or joins two components and may be used interchangeably. Linkers may comprise functional groups enabling the conjugation of active agents to the peptide. Linkers or spacers may provide for optimal spacing of components of the fusion peptide, for example providing flexibility to the construct and enabling each component of the construct, including any active agent conjugated to the fusion peptide, to interact with its respective target, and optimise or increase cell uptake and activity.

[0133] The linker may be a flexible or rigid linker. Suitable linkers include, by way of example only, amino acids such as aminohexanoic acid, 4-aminobutryic acid, 8-aminooctanoic acid, lysine, glycine and serine and stretches of two or more amino acids such as glycine and serine (e.g. GS, (G4S)n, or (G)n). Linkers such as aminohexanoic acid and lysine allow for the conjugation of moieties such as active agents to the peptide via an amide.

[0134] In an exemplary embodiment, the cell-penetrating peptide comprises a diglycine (GG) linker between components (i) and (ii). In another exemplary embodiment, the cell- penetrating peptide may comprise an aminohexanoic acid moiety between components (i) and (ii), and / or at the C-terminus of the cell-penetrating peptide, typically at the C-terminus of the peptide sequence comprising the amino acid sequence of SEQ ID NO:7 or 8, or sequence at least about 90% identical thereto.

[0135] Other suitable linkers may comprise a functional group, optionally a thiol group, to facilitate conjugation of an active agent to the cell-penetrating peptide. Exemplary thiol group-containing linkers for functionalization of the cell-penetrating peptide include, for example, cysteine and thiopropionic acid (TPA). For example, a cysteine residue may be incorporated at the N-terminus or C-terminus of a peptide, optionally the C-terminus, to enable "click” conjugation of a moiety such as an oligonucleotide optionally functionalized with maleimide (e.g. Patil et al., 2019, Bioconjug Chem 30:793-799).

[0136] Linkers may further supply a labile linkage that allows the two components to be separated from each other. Labile linkages include photocleavable groups, acid-labile moieties, base-labile moieties and enzyme-cleavable groups.

[0137] Linkers may be incorporated between components of the cell-penetrating peptide and / or at the N-terminal and / or C-terminal ends of the cell-penetrating peptide to provide flexibility enabling each component of the cell-penetrating peptide, access to interact with their respective target(s) and receptor(s) facilitating cellular uptake and activity. As an alternative, or in addition to one or more of the above-described linkers, moieties of variable length may be employed, including for example polyethylene glycol (PEG) moieties. The PEG moiety may be a short, or ‘mini-PEG’ spacer of 2, 3, 4, 5 or 6 (or longer) unit length. Exemplary mini-PEG spacers are:

[0138] Amino-PEG2 -acetic Acid Amino-PEG3 -acetic Acid

[0139] Amino-PEG5-Propionic acid

[0140] The endosomal escape domain comprises a moiety that prevents endosomal entrapment and / or facilitates removal or escape of the cell-penetrating peptide, and any moiety linked to the cellpenetrating peptide, from endosomal compartments or vesicles within endothelial cells following crossing of the blood-brain barrier or a blood-ocular barrier. Typically, the endosomal escape domain comprises a pH-dependent endosomal membrane disrupting moiety. In particular embodiments, the endosomal escape domain comprises a peptide sequence. By way of example, the peptide sequence may comprise an N-terminal fragment of the influenza virus hemagglutinin subunit HA2, a GALA peptide or a nuclear localisation sequence. In one exemplary embodiment the fragment of HA2 comprises the amino acid sequence of SEQ ID NO:9, a derivative thereof, or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto.

[0141] Exemplary cell-penetrating peptides that can be linked or conjugated to BCN peptides described hereinbefore include those described in co-pending International Patent Application No. PCT / AU2021 / 051255, the disclosure of which is incorporated herein in its entirety. In particular exemplary embodiments, the cell-penetrating peptide comprises or consists of the sequence set forth in SEQ ID NO:10, SEQ ID NO:11 or SEQ ID NO:12. More particularly, the cell-penetrating peptide comprises or consists of the sequence set forth in SEQ ID NO:11 . The cell-penetrating peptide may be acetylated at the N-terminus, or may be myristoylated at the N-terminus.

[0142] Embodiments of the disclosure contemplate derivatives of cell-penetrating peptide sequences disclosed herein. As used herein the term "derivative" is intended to encompass chemical modification to a peptide or one or more amino acid residues of a peptide, including chemical modification in vitro, for example by introducing a group in a side chain in one or more positions of a peptide, such as a nitro group in a tyrosine residue or iodine in a tyrosine residue, by conversion of a free carboxylic group to an ester group or to an amide group, by converting an amino group to an amide by acylation, by acylating a hydroxy group rendering an ester, by alkylation of a primary amine rendering a secondary amine, or linkage of a hydrophilic moiety to an amino acid side chain. Otherderivatives may be obtained by oxidation or reduction of the side-chains of the amino acid residues in the peptide. Modification of an amino acid may also include derivation of an amino acid by the addition and / or removal of chemical groups to / from the amino acid, and may include substitution of an amino acid with an amino acid analog (such as a phosphorylated or glycosylated amino acid) or a non-naturally occurring amino acid such as a N-alkylated amino acid (e.g. N-methyl amino acid), D-amino acid, 0- amino acid or y-amino acid.

[0143] A cell-penetrating peptide of the present disclosure may further comprise one or more additional moieties. For example, a lipid moiety, such as a myristoyl group, may be attached to the N-terminal end of the fusion peptide, optionally to the N-terminal end of the endosomal escape domain. The conjugate may comprise a moiety to facilitate or enhance uptake by brain cells, such as a folate moiety (for example 5-methyltetrahydrofolate) to bind to the folate receptor or sugar moiety (for example glucose or N-acetyl- galactosamine) to bind to class I hexose (glucose) transporters.

[0144] The cell-penetrating peptide may be linked to another cell-penetrating peptide that is effective to enhance transport and cellular penetration and uptake, such as for example, an arginine-rich peptide transporter, Penetratin or the Tat peptide. These peptides are well known in the art and are disclosed, for example, in US Publication No. 20100016215.

[0145] Cell-penetrating peptides such as those described above may be linked or conjugated to BCN peptides disclosed herein to improve cellular penetration and uptake of the BCN peptides. The cellpenetrating peptide may be linked or conjugated to the N- terminus or C-terminus of the BCN peptide. In exemplary embodiments, the -penetrating peptide is linked or conjugated to the N-terminus of the BCN peptide. The cell-penetrating peptide and the BCN peptide may be directly attached to one another or may be attached via one or more linkers or spacers. Suitable linkers and spacers are as described hereinbefore. In an exemplary embodiment, a diglycine (GG) linker is incorporated between the cellpenetrating peptide and the BCN peptide.

[0146] In exemplary embodiments, a cell-penetrating peptide having a sequence as set forth in SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, or a sequence at least of about 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, is linked or conjugated to the N-terminus of a BCN peptide having a sequence as set forth in SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6, or a sequence at least of about 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, optionally via linker such as a diglycine (GG) linker.

[0147] In the context of fusion peptides described herein, the terms "linked", "attached" and "conjugated" are used interchangeably and relate to any type of interaction that conjugates (joins) two or more peptides and include covalent bonds or non-covalent bonds, such as, for example, hydrophobic / hydrophilic interactions, van der Waals forces, ionic bonds, disulphide bonds or hydrogen bonds. In an exemplary embodiment, two or more peptide components are joined via a linker or spacer sequence or moiety.

[0148] A BCN peptide, cell-penetrating peptide or fusion peptide comprising a BCN peptide and a cellpenetrating peptide, as described herein may further comprise one or more additional active agents attached thereto, for example at eitherterminus or via a linker or spacer as described hereinbefore (e.g. via a linker such as a cysteine residue or TPA). The active agent may be, for example, a therapeutic agent, a diagnostic agent, a detection agent or an agent for imaging biological tissue. Suitable active agents include nucleic acid-based constructs such as antisense oligonucleotides and protein-, polypeptide- or peptide-based moieties. Conjugation of active agents to the peptides can be achieved using a variety of conjugation chemistry techniques that will be well known to those skilled in the art. By way of example, suitable techniques are described in: Karas et al., 2018, Methods Mol Biol 1828:355- 363; Patil et al., 2019, Bioconjug Chem 30:793-799; Shabanpoor and Gait, 2013, Chem Commun (Camb) 49:10260-10262; and Shabanpoor et al., 2015, Nucleic Acids Res 43:29-39. To facilitate the generation of branched conjugates, in which the active agent is conjugated between the endosomal escape domain and the ApoE sequence, or between the ApoE sequence and the BCN peptide, the fusion peptide may include an amino acid residue, such as lysine, cysteine or aminohexanoic acid, to facilitate conjugation, optionally via a functional group such as TPA.

[0149] The additional active agent may be a therapeutic agent suitable for use in the treatment or prevention of any disease or disorder, wherein the site of action of the agent is within the central nervous system, requiring that the agent crosses the blood-brain barrier, or wherein the site of action of the agent is within the eye, requiring that the agent crosses a blood-ocular barrier. The skilled person will appreciate that the scope of the present disclosure is not limited by reference to any specific type or identity of therapeutic agent. For example, the disease or disorder may be a disease or condition of the CNS, such as a neurodegenerative disease or condition or an ocular disease or condition.

[0150] The peptide sequences comprising the peptides of the present disclosure may be produced using any method known in the art, including synthetically or by recombinant techniques such as expression of nucleic acid constructs encoding the components. For example, a peptide may be synthesized using the Fmoc-polyamide mode of solid-phase peptide synthesis. Other synthesis methods include solid phase t-Boc synthesis and liquid phase synthesis. Purification can be performed by any one, or a combination of, techniques such as re-crystallization, size exclusion chromatography, ion-exchange chromatography, hydrophobic interaction chromatography and reverse-phase high performance liquid chromatography using, for example, acetonitrile / water gradient separation. Fusion peptides may be synthesised as a single peptide sequence, including where appropriate one or more amino acid or peptide linkers. Alternatively, components of fusion peptides may be synthesised individually and may be conjugated or linked post-synthesis by suitable techniques known to those skilled in the art.

[0151] A fusion peptide of the present disclosure may be produced when two or more heterologous nucleotide sequences encoding each component of the fusion peptide, optionally including nucleotides sequences encoding a linker or spacer amino acid(s), are fused together in the correct translational reading frame and are expressed. Accordingly, the present disclosure also provides isolated nucleic acid molecules encoding peptides and fusion peptides and components thereof as described herein.

[0152] The present disclosure also provides vectors comprising a nucleotide sequence(s) encoding peptide sequences and fusion peptides described herein. Typically, the nucleotide sequence(s) is operably linked to a promoter to allow for expression of the peptide or fusion peptide. The vectors can be episomal vectors ( / .e., that do not integrate into the genome of a host cell), or can be vectors that integrate into a host cell genome. Vectors may be replication competent or replication-deficient. Exemplary vectors include, but are not limited to, plasmids, cosmids, and viral vectors, such as adeno- associated virus (AAV) vectors, lentiviral, retroviral, adenoviral, herpesviral, parvoviral and hepatitis viral vectors. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

[0153] Therapeutic Methods and Uses

[0154] As exemplified herein, the inventors have incorporated the cell-penetrating peptide of SEQ ID NO:11 to the N-terminus of the BCN peptides disclosed herein. The resultant fusion peptides show higher cellular uptake and autophagy-inducing efficacy compared to the BCN peptides alone. The most potent autophagy-inducing fusion peptide exemplified herein, represented by SEQ ID NO:13, was administered continuously via intra- cerebroventricular (ICV) infusion or systemically via tail vein (IV) injection in a reporter mouse model of autophagy. The analysis of spinal motor neurons (MNs) showed significant upregulation of autophagy in the spinal motor neurons, indicating the clinical utility of the fusion peptide as an autophagy-inducing therapeutic for neurodegenerative diseases, including motor neuron diseases such as amyotrophic lateral sclerosis.

[0155] Accordingly, provided herein are methods for inducing or increasing autophagy in a cell, comprising exposing the cell to a BCN peptide, or fusion peptide comprising a cell- penetrating peptide linked to a BCN peptide, of the present disclosure. The method may be performed ex vivo or in vivo. The cell may be any suitable cell in which it is desirable to induce or increase autophagy, such as a cell in, or derived from, a subject having, predisposed to, or at risk of developing a disease or condition associated with impaired autophagy. The cell may be a post-mitotic cell, such as, for example, a skeletal muscle cell or a neuronal cell. Exemplary cells include, but are not limited to, cells of central nervous system, including neuronal cells such as motor neurons, and glial cells (astrocytes, microglia and oligodendrocytes).

[0156] Also provided herein are methods fortreating diseases and conditions associated with impaired autophagy, comprising administering to a subject in need thereof an effective amount or dose of a BCN peptide, or fusion peptide comprising a cell-penetrating peptide linked to a BCN peptide, of the present disclosure. The subject may be suffering from, having, predisposed to, or at risk of developing a disease or condition associated with impaired autophagy. Exemplary diseases and conditions include, but are not limited to cancer, cardiovascular diseases, diseases of the liver or kidneys, diseases or conditions associated with aging, immune system diseases including autoimmune diseases, muscular diseases, metabolic disorders such as diabetes, inflammation including inflammatory bowel disease, ocular diseases such as age-related macular degeneration, diabetic retinopathy and glaucoma, infectious diseases, neurological diseases and neurodegenerative diseases. (See, for example, Klionsky et a / ., 2021 , EMBO J 40:e108863; Lu et al., 2022, MedComm(2020) 10(3):e150). Exemplary neurological and neurodegenerative diseases and conditions include, but are not limited to, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, amyotrophic lateral sclerosis, tauopathies (such as, for example, frontotemporal lobar degeneration and progressive supranuclear palsy), spinal muscle atrophy, epilepsy, seizures, stroke, multiple sclerosis, ankylosing spondylitis, spinal stenosis and spina bifida.

[0157] In the majority of neurodegenerative diseases, there is an over-accumulation of autophagosomes, suggesting an impairment in the autolysosome formation and degradation steps. It is therefore beneficial in these contexts to utilise a therapeutic agent that promotes autolysosome formation or autophagy flux, rather than only autophagosome formation. In exemplary embodiments, peptides and fusion peptides comprising the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:4, including fusion peptides comprising the amino acid sequence of SEQ ID NO:13 or SEQ ID NO:14, may be advantageously employed to induce autophagy in the treatment of neurodegenerative diseases.

[0158] For in vivo methods contemplated herein, the route of the administration of the peptides and fusion peptides is not limited. For example, an effective amount of a peptide can be administered to a subject via, for example, intravitreal, intrathecal, intracerebroventricular, intravenous, intraperitoneal, subcutaneous, epicutaneous, intradermal, intramuscular, pulmonary, oral, buccal, or nasal routes. In exemplary embodiments, the peptide may be administered by intravenous administration. The peptide can be administrated as a single dose or multiple doses, and at varying intervals. In particular embodiments administration may comprise multiple doses be for a period of days, weeks or months, depending on a variety of the peptide administered, the route of administration, the severity of the condition to be treated and the general health and wellbeing of the subject.

[0159] Those skilled in the art will appreciate that in accordance with the methods of the present disclosure peptides described herein may be administered alone or in conjunction with one or more additional compounds or agents for treating the disease or condition associated with impaired autophagy that is to be treated using the peptide of the disclosure. For such combination therapies, each component of the combination therapy may be administered at the same time, or sequentially in any order, or at different times, so as to provide the desired effect. Alternatively, the components may be formulated together in a single dosage unit as a combination product. When administered separately, it may be preferred for the components to be administered by the same route of administration, although it is not necessary for this to be so.

[0160] The peptides are typically administered to subjects in the form of pharmaceutical compositions. Suitable compositions for use with the methods of the invention may be prepared according to methods and procedures that are known to those of ordinary skill in the art and accordingly may include pharmaceutically acceptable carriers, diluents, excipients and / or adjuvants. The diluents, adjuvants and excipients should be "acceptable" in terms of being compatible with the other ingredients of the composition, and not deleterious to the recipient thereof.

[0161] Examples of pharmaceutically acceptable carriers, diluents excipients and / or adjuvants include demineralised or distilled water; saline solution; hydrophilic polymers such as polyvinylpyrrolidone; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants such as Tween™, Pluronics™ or polyethylene glycol (PEG); silicone oils, including polysiloxanes, such as methyl polysiloxane, phenyl polysiloxane and methylphenyl polysolpoxane; volatile silicones; mineral oils such as liquid paraffin, soft paraffin or squalane; cellulose derivatives such as methyl cellulose, ethyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose or hydroxypropylmethylcellulose; lower alkanols, for example ethanol or iso-propanol; lower aralkanols; lower polyalkylene glycols or lower alkylene glycols, for example polyethylene glycol, polypropylene glycol, ethylene glycol, propylene glycol, 1 ,3-butylene glycol or glycerin; and fatty acid esters such as isopropyl palmitate, isopropyl myristate or ethyl oleate.

[0162] One skilled in the art would be able, by routine experimentation, to determine an effective, nontoxic amount of a pharmaceutical composition which would be required to achieve the desired therapeutic effect. For example, an effective dosage may be in the range of about 0.0001 mg to about 1000mg per kg body weight per 24 hours; typically, about 0.001 mg to about 750mg per kg body weight per 24 hours; about 0.01 mg to about 500mg per kg body weight per 24 hours; about 0.1 mg to about 500mg per kg body weight per 24 hours; about 0.1 mg to about 250mg per kg body weight per 24 hours; about 1 .Omg to about 250mg per kg body weight per 24 hours. More typically, an effective dose range is expected to be in the range about 1 .Omg to about 200mg per kg body weight per 24 hours; about 1 .Omg to about 100mg per kg body weight per 24 hours; about 1.0mg to about 50mg per kg body weight per 24 hours; about 1 .Omg to about 25mg per kg body weight per 24 hours; about 5. Omg to about 50mg per kg body weight per 24 hours; about 5.0mg to about 20mg per kg body weight per 24 hours; about 5.0mg to about 15mg per kg body weight per 24 hours.

[0163] The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

[0164] The present disclosure will now be described with reference to the following specific examples, which should not be construed as in any way limiting the scope of the disclosure.

[0165] Examples

[0166] The following examples are illustrative of the disclosure and should not be construed as limiting in any way the general nature of the disclosure of the description throughout this specification.

[0167] Example 1 - Experimental procedures: Peptide synthesis and characterization Reagents

[0168] Paraformaldehyde (PFA), collagen (type I solution from rat tail), protease inhibitor cocktail, rabbit LC3 antibody (L7543), mouse -actin antibody (A5316), mouse anti-Neuronal nuclear antigen (NeuN, MAB377), ALT assay kit (MAK052), human serum, bafilomycin A1 (BafA1) and rapamycin (Rapa) were purchased from Sigma-Aldrich (Sydney, Australia). SDS polyacrylamide gels (4-12%), low fluorescent PVDF membranes (0.45 pm) and trans-blot turbo transfer buffer were obtained from Biorad (Sydney, Australia). Mouse p62 antibody (AB56416), rabbit anti-lysosomal-associated membrane protein 1 (LAMP1 , AB24170), rabbit anti-GFP (AB290) and IgG Enzyme-linked immunosorbent assay (ELISA) kit (AB151276) were purchased from Abeam (Melbourne, Australia). IRDye 680 goat anti-mouse and IRDye 800CW goat anti-rabbit conjugated secondary antibodies and molecular weight marker were obtained from Li-Cor (Lincoln, USA). Glass slides, prolong Diamond Antifade Mountant, Dulbecco’s modified eagle medium (DMEM), penicillin / streptomycin (Pen / Strep), L-glutamine, lipofectamine 2000® and Alexa Fluor 647 anti-mouse secondary antibody (A22287) were purchased from ThermoFisher Scientific (Melbourne, Australia). Dako fluorescent mounting medium was obtained from Agilent (Melbourne, Australia). NSC-34 cells were purchased from Cedarlane Laboratories (Burlington, Canada). Lethabarb was obtained from Virbac (Sydney, Australia). p-Slide 4 Well Ph+ Glass Bottom chamber slides (80447) were purchased from Ibidi GmbH (Munich, Germany). CellTiter 96® AQueous One Solution Cell proliferation Assay (G3582) was purchased from Promega (Madison, USA). Mini osmotic pumps (model 2004) were obtained from Azlet (California, USA). Dy Light 405 anti-rabbit secondary antibody (711-475- 152) was purchased from Jackson ImmunoResearch Laboratories (Chester, USA). NfL ELISA kit (MBS109377) was purchased from MyBioSource (San Diego, USA).

[0169] Peptide synthesis

[0170] The synthesis of Beclin 1 analogue peptides were carried out using the standard 9- Fluorenylmethoxycarbonyl (Fmoc) solid-phase peptide synthesis. Peptides (0.1 mmol scale) were synthesised on TentaGel® XV resin (100-200 mesh, loading: 0.20 mmol / g). The N-terminal Fmoc protecting groups were removed by treating the resin-attached peptide with piperidine (20% v / v) in dimethylformamide (DMF). For peptides that were synthesised manually, a 5-fold molar excess of Fmoc-protected amino acids (0.5 mmol) was activated with a 5-fold excess of 1- [Bis(dimethylamino)methylene]-1 H-1 ,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate, hexafluorophosphate azabenzotriazole tetramethyl uranium (HATU) in the presence of 10-fold excess of N, N-Diisopropylethylamine (DIEA; 1 mmol) [206, 207], For peptides that were synthesised on Liberty peptide synthesiser, the coupling was carried out using a 4-fold excess of Fmoc-protected amino acids (0.4 mmol) in the presence of 4-fold excess N, N'-Diisopropylcarbodiimide (DIC) and 4-fold excess of Ethyl cyano(hydroxyimino)acetate (Oxyma) at 90 °C for 5 mins in DMF. The first amino acid and Fmoc- Arg(pbf)-OH were double coupled, and Fmoc-Cys(Trt)-OH and Fmoc-His(Trt)-OH were coupled at 50 °C for 10 mins.

[0171] The N-terminus of the solid phase-bound peptides were acetylated with acetic anhydride (5 eq) in DMF in the presence of DIEA (10 eq) or chloroacetic acid (4 eq) activated with HATU (4 eq) in DMF in the presence of DIEA (8 eq). The success of N-terminal capping was tested using the colourimetric 2,4,6-trinitrobenzene sulphonic acid (TNBSA) test, which detects free amine. In the presence of free amine, the resin developed a red colour, and the absence of red colouration of the resin indicated successful capping. The resin-bound peptide chain was cleaved from the solid support by treatment with a cocktail of 20 mL of trifluoroacetic acid (TFA): 3,6-dioxa-1 ,8-octanedithiol (DODT): H2O: triisopropylsilane (TIPS) (94:2.5:2.5:1 % v / v) for 90 mins at room temperature (RT). Excess TFA was evaporated by blowing nitrogen gas into the peptide-TFA solution. The cleaved peptide was precipitated in ice-cold diethyl ether and centrifuged at 3,000 rpm for 3 min. The peptide pellet was washed with ice- cold diethyl ether twice more to remove excess TFA and scavengers.

[0172] Disulfide bond formation: The formation of the disulfide bond in BCN (BCN1 (SS)) peptide was carried out in solution. The linear purified BCN1 (SS) peptide was dissolved in water (1.5 mg / ml), and 2,2'- dipyridyld isulfide (DPDS) (5 eq.) in methanol was added dropwise to the stirring solution of the peptide. The reaction was stirred at RT for 1 h. The progression of the reaction was monitored by reversed- phase high-performance liquid chromatography (RP-HPLC). The completion of the reaction was confirmed with ESI and the colourimetric Ellman test.

[0173] Thioether bond formation: The synthesis of the thioether bond in BCN (BCN1 (OX)) peptide was carried out in solution by preparing 1 mM solution of purified linear peptide in acetonitrile (ACN) / H2O with 20 mM ammonium bicarbonate (NH4HCO3), pH 8.0. The o-xylene linker (1.5 eq) dissolved in ACN was added to the peptide solution and incubated at RT for2 h. The progression ofthe reaction was monitored by RP-HPLC, and the completion ofthe reaction was confirmed with the Ellman test and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF, Shimadzu) mass spectrometry.

[0174] Lactam bond formation: The linear form of lactam-stapled BCN (BCN1 (EK)) peptide was synthesised with hydrazine labile side-chain protecting groups on Lys(ivDde)-OH and Glu(ODmab)-OH. The protecting groups were removed by treating the resin with 4% hydrazine in DMF (3 x 5 min). The lactam bridge was formed using HATU (4 eq), 1-hydroxy-7-azabenzotriazole (HOAt; 2 eq; GL Biochem) and DIEA (8 eq) at RT for 2 h. Once the completion of the reaction was confirmed with the TNBSA test, any unreacted Lys (NH2) was acetylated with acetic anhydride (5 eq) in DMF in the presence of DIEA (10 eq). The resin-bound peptide was cleaved using the TFA cleavage cocktail.

[0175] Labelling peptides with sulfo- cyanine5 (Cy5): The purified peptides, BCN4 and CPP-BCN4 with a C- terminal cysteine residue (1 eq), were dissolved in phosphate-buffered saline (PBS, pH 7.4), and maleimide-sulfo-Cy5 (3 eq) dissolved in PBS was added to the peptide solution. The progression of the reaction was monitored with MALDI-TOF mass spectrometry, and the absence of peptide mass confirmed the completion of the reaction.

[0176] Peptide purification and characterization

[0177] Crude peptides were dissolved in distilled water, analysed and purified by RP-HPLC on Phenomenex Jupiter columns (4.6 x 250 mm, C18, 5 pm) and (21.2 x 150 mm, C18, 5 pm) using 0.1% TFA in water and ACN as buffer A and B respectively. A gradient of 20 to 50% buffer B over 30 min was used at a flow rate of 1.5 mL min'1for the analytical and 10 mL min-1 for the preparative column. All peptides were purified to greater than 95% purity as determined by analytical RP-HPLC (not shown). The molecular masses of peptides were determined with MALDI-TOF mass spectrometry, using a- cyano-4-hydroxy-cinnamicacid (CHCA) in 50% ACN containing 0.1% TFA orsinapinic acid (SA) in 75% acetonitrile containing 0.1 % TFA as matrices (not shown). Purified peptides were freeze-dried and stored at -20°C. All peptides were dissolved in 2 mM hydrochloric acid (HCI) and lyophilised to remove residual TFA counterion and replace it with a safer chloride salt. The lyophilised peptides were dissolved in milli-Q water, and quantifications were carried out using a Direct Detect® spectrometer (Millipore).

[0178] In vitro autophagy activity

[0179] To evaluate the effect of peptides on autophagy activity in vitro, the hybrid cell line produced by the fusion of embryonic spinal cord motor neurons (MNs) with mouse neuroblastoma cells N18TG2 (NSC-34) was used.

[0180] Immunocytochemistry was utilised to visualise the autophagic vesicles. In a 24-well plate, 13 mm, No. 1.5H coverslips were coated with collagen, type I solution from rat tail. Cells were then subcultured with complete medium consisting of Dulbecco’s modified eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% penicillin / streptomycin (Pen / Strep) and 1 % L- glutamine (200 nM). Cells were grown overnight, for at least 18 h, before being transfected with pDest- mCherry-EGFP-LC3B plasmid (1 pg / well; a gift from Dr Serhiy Pankiv (Pankiv, et al., 2007)) using Lipofectamine 2000® (3 pL / well) in FBS-free medium. After 1 h, cells were topped up with 20% FBS- containing medium and grown overnight. Subsequently, cells were treated with 5 pM HA2, ApoE, CPP, CPP-Scram BCN1 , BCN1 , ChAc-BCN1 (SS), BCN1 (SS), BCN1 (OX), BCN1 (EK), CPP-BCN1 , BCN2, CPP-BCN2, BCN3, CPP-BCN3, BCN4 and CPP-BCN4, 0.1 , 1.25, 2.5, 5, 10, 20 and 40 pM CPP-BCN4, 5 and 20 pM TAT-BECN1 or 0.55 pM of Rapa in complete medium for 24 h. To inhibit autophagy, cells were treated with 0.4 pM BafA1 in complete medium for 6 h. To induce starvation, cells were incubated for 24 h in DMEM, supplemented with 1 % Pen / Strep and 1% L-glutamine but without the FBS. Cells were rinsed with ice-cold DPBS and fixed with ice-cold 4% (w / v) paraformaldehyde (PFA) for 10 min on ice. Subsequently, the cells were washed for 3 x 5 min with ice-cold PBS and stained in the dark with Hoechst 33342 (0.001 mg / mL) in PBS for 10 min. Cells were washed with 3 x 5 min with PBS. Coverslips were mounted on glass slides using fluorescent mounting medium, and slides were dried overnight. Cells were imaged using the Leica SP8 Resonant Scanning confocal microscopy with the 63x / 1 .4 oil objective. Random sampling was used to acquire 20 images per slide. Z-stacks were taken through the cells, and the maximum intensity projection image was used for analysis. Autophagy flux was calculated manually from 20 transfected cells.

[0181] Western blotting was utilised to quantify autophagy proteins. Cells were sub-cultured in a 6-well plate with complete medium. Cells were grown overnight for at least 18 h. Subsequently, cells were treated with 5, 10 and 20 pM CPP-BCN4 in complete medium for 24 h. Subsequently, cells were rinsed with DPBS and lysed with lysis buffer containing 20 mM Tris-CI (pH 7.4), 150 mM NaCI, 1 % detergent Triton-X 100 and freshly added 1 % protease inhibitor cocktail and phosphate inhibitors [50 mM sodium fluoride (NaF) and 10 mM sodium orthovanadate (NaaVCU)] for 20 min on ice. Lysates were collected and centrifuged at 14,000 rpm for 20 min at 4°C.

[0182] The protein concentration in the supernatants was quantified using the Direct Detect™ infrared (IR)-based spectrometer (Millipore). Protein samples (20 pg) were diluted 5:1 with 5 X sodium dodecyl sulphate (SDS) buffer solution consisting of 50% glycerol, 1 M Tris-CI, pH 6.8, 10% SDS, 5% glycine and 0.25% bromophenol blue, and 10% p-mercaptoethanol. The samples were then boiled for 5 min at 100 °C.

[0183] The remaining pellets were washed with the lysis bufferto remove residual soluble proteins. The pellets were then lysed with 8 M urea, 5% (w / v) and SDS, 1 % protease inhibitor cocktail and phosphate inhibitors (50 mM sodium fluoride (NaF) and 10 mM sodium orthovanadate (NaaVCU)), freshly made in milli-Q water. The samples were then sonicated with Q55 Sonicator (Qsonica) at 50% output for 5 sec. They were left at RT for 20 min and then centrifuged at 23,000 g for 20 min at RT to get the Triton-X 100 insoluble fraction. An equal volume of pellet lysates (40 pL / sample) was diluted 5: 1 with 5 X SDS buffer solution and 10% p- mercaptoethanol.

[0184] Samples were then loaded onto 4-12% SDS polyacrylamide gels, along with molecular weight standards. Subsequently, gels were electrophoresed in a running buffer containing 0.1 % (w / v) SDS and 14.8% (w / v) glycine in 100 mM Tris-HCI at pH 8.25 at 60 V for 30 min and then at 100 V for 60-90 min. After the electrophoresis was complete, the proteins in gels were transferred to 0.45 pm low fluorescent PVDF membranes using trans-blot turbo transfer buffer via Trans-Blot® Turbo™ Blotting System (BioRad). The high molecular weight programmed method (at 25 V for 10 min) was used. Once transferred, membranes were blocked in a blocking buffer containing 5% (w / v) skim milk powder and 0.02% (w / v) sodium azide (NaNa) in Tris-buffered saline with Tween-20 (TBST, pH 8.0) for 30 min at RT. Membranes were then washed 3 x with TBST and incubated overnight at 4 °C with rabbit LC3 antibody (1 : 1000, Sigma, L7543), mouse p62 antibody (1 :500) and the internal standard, mouse -actin antibody (1 :2,000), diluted in 3% (w / v) bovine serum albumin and 0.02% (w / v) NaNa in TBST. NaNa was added to the primary diluent solution to prevent microbial contamination and allow the solution to be reused. The following day, membranes were washed 3 x in TBST for 10 min and incubated in the dark with IRDye 680 and 800CW conjugated secondary antibodies (1 :10,000) diluted in TBST for 30 min, followed by another cycle of 3 x 10 min TBST washes. Protein bands were visualised and imaged with ChemiDoc™ MP Imaging System (Bio-Rad) and analysed with the Image Lab software (version 6.0.1). The intensity of the protein band of interest was quantified by subtracting its mean intensity from background intensity and normalising it to the intensity of the band representing the loading control, -actin, or the total protein.

[0185] In vitro analysis of protein aggregates

[0186] To analyse the effect of the peptide on protein aggregates in vitro, immunocytochemistry was utilised as above. NSC-34 cells were transfected with EGFP or 101x EGFP-tagged PR, PA, GA, and GR (Radwan, et al., 2020) (1 pg / well) using Lipofectamine 2000® (3 pL / well) in FBS-free medium. After 1 h, cells were topped up with 20% FBS-containing medium and grown for 48 h ortreated with 10 pM CPP- BCN4 for 48 h.

[0187] Cell uptake and confocal imaging

[0188] To analyse the intracellular levels of the peptides in vitro, NSC-34 cells were sub-cultured at 6.0 x 104cells / well density with complete medium in p-Slide 4 Well Ph+ Glass Bottom chamber slides. After 24 h, cells were treated with 5 pM Cy5-labelled BCN4 or CPP-BCN4 peptides in Opti-MEM Medium for 30 min, 1 h, 2 h or 3 h. Cells were stained with Hoechst 33342 (0.001 mg / mL) in PBS for 10 min and then washed with DPBS. Cells were live imaged using the Leica SP8 Resonant Scanning confocal microscopy with the 63x / 1 .4 oil objective.

[0189] Cell viability

[0190] To analyse the toxicity of the peptide in vitro, NSC-34 cells were sub-cultured in a 96-well plate. Cells were grown overnight, for at least 18 h, before being treated with 0.01 , 0.1 , 1 , 10, 20, 30, 40, 50 and 100 pM CPP-BCN4 for 24 h. To assess the cell viability, the CellTiter 96® AQueous One Solution Cell Proliferation Assay was used. CellTiter 96® AQueous One Solution Reagent (20 pL / well) was added directly to cells for 1 h. Viable, metabolically active cells were quantified with a microplate reader by measuring the optical density at an absorbance of 490 nm of coloured formazan generated from reducing tetrazolium compound, 3-(4,5-Dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H- tetrazolium (MTS). Experiments were performed in triplicates. To calculate the cell viability, the average absorbance of background controls (wells with MTS solution but no cells) was subtracted from the absorbance of each sample. Subsequently, the average absorbance of treated samples corrected for background signals was taken and normalised to that of untreated samples corrected for background signals.

[0191] Proteolytic serum stability

[0192] To evaluate the proteolytic stability of CPP-BCN4, 50 nmol aliquots of the peptide were dissolved in 100 |jl_ of 50% human serum and incubated for 10 mins, 30 mins, 1 h, 4 h and 24 h. At the end of each time point, 200 pL of 1M guanidinium chloride (GdmCI) solution containing freshly added 1% protease inhibitor cocktail was added to the peptide-serum solution. Subsequently, 600 pL of ice-cold ACN was added to precipitate serum proteins, and the solution was centrifuged at 14,000g for 3 mins at 4°C. The supernatants were transferred to another set of clean Eppendorf tubes and were lyophilised. The lyophilised samples were dissolved in 500 pL of milli-Q water, and 20 pL of 1 mM phenol was added. The peptide solution (400 pL) was analysed using RP-HPLC on the Phenomenex Jupiter column (4.6 x 250 mm, C18, 5 pm) using 0.1% TFA in water and ACN as buffer A and B, respectively. A gradient of 10 to 70% buffer B over 30 min was used at a flow rate of 1.5 mL min'1. The area under the peak corresponding to the intact peptide for each time point was quantified and used to calculate the half-life of the peptide in serum.

[0193] Mouse experiments

[0194] All mouse experiments adhered to the Australian National Health and Medical Research Council published code of practice for animal research and were approved by the Florey Institute of Neuroscience and Mental Health Animal Ethics Committee. The cytomegalovirus immediate early enhancer / chicken -actin (CAG)-red fluorescent protein (RFP) -enhanced green fluorescent protein (EGFP)- microtubule-associated protein 1 A / 1 B-light chain 3 (LC3) reporter mice (CAG- RFP-GFP-LC3 mice) and SOD1 (G93A) mice were bred to C57BL / 6 mice. Animals were kept in a temperature- controlled room (22 °C) under a 12-h light / dark cycle with ad libitum access to food and water. The mice were randomly assigned to one of the treatment groups, and the experimenter was blind to the treatment groups throughout the study.

[0195] CAG- RFP-GFP-LC3 mice

[0196] Peptide treatment (2 weeks). A group of CAG-RFP-EGFP-LC3 mice at postnatal day 60 (P60) were treated with saline (vehicle) and CPP-BCN4 dissolved in saline at 10 pg / day via ICV mini-osmotic pumps for 2 weeks. Another group of CAG-RFP-EGFP-LC3 mice at P60 were treated via IV injections with saline, CPP-Scram BCN4 and CPP-BCN4 dissolved in saline at 10 mg / kg twice a week for 3 weeks.

[0197] At the end of the treatment periods, general anaesthesia was induced in mice by lethal intraperitoneal (IP) injection of 100 mg / kg of sodium pentobarbitone (Virbac). A syringe with a 25-gauge needle was used to puncture the heart to collect blood. The blood was left to coagulate and then centrifuged for 10 mins at 6, 000 rpm. The serum was collected and frozen at -80 °C.

[0198] Mice were perfused, and their lumbar spinal cord were dissected out and post- fixed in 4% PFA for 2 h at room temperature. Subsequently, the lumbar spinal cords were cryoprotected in 30% (w / v, pH 7.4) sucrose in PBS at 4 °C until tissues had sunk.

[0199] SOD1 G93A mice

[0200] Peptide treatment (survival study). Transgenic SOD1G93A mice at P45 were treated with CPP- BCN4 and CPP-Scram BCN4 (10mg / kg / week for 10 weeks, n=12 / group) via intravenous (IV) injections. One mouse reached end-stage; general anaesthesia was induced in mice by lethal intraperitoneal (IP) injection of 100 mg / kg of lethabarb. Blood was collected through cardiac puncture using 25-G needle. The blood was left to coagulate and then centrifuged for 10 mins at 6,000 rpm. The serum was collected and frozen at -80 °C.

[0201] In vivo autophagy activity

[0202] Immunohistochemistry was used to analyse the effect of the peptide on autophagy activity in vivo. The lumbar spinal cords were embedded in an optimal cutting temperature and frozen at -80 °C. They were then cut using a Leica CM 1850 UV cryostat at 20 pm cross-section, 1 in 10, onto glass slides. The tissues on the slides were dried before being washed 3 times in PBS, 5 mins each. Subsequently, tissues were permeabilised and blocked for 1 h at RT in 0.3% (v / v) Triton-X 100 in PBS containing 10% (v / v) donkey serum. The primary antibody, rabbit anti-Lysosomal-associated membrane protein 1 (LAMP1 , 1 :50) and / or mouse anti-Neuronal nuclear antigen (NeuN, 1 :100), was prepared in antibody diluent buffer containing 0.3% Triton-X 100 in PBS and 1 % donkey serum. The tissues were incubated with the primary antibody overnight at 4 °C. The following day, tissues were washed 3 times in PBS, 5 mins each and blocked in 0.3% (v / v) Triton-X 100 in PBS containing 10% (v / v) donkey serum (Millipore). Tissues were then incubated with secondary antibody (DyLight 405 anti-rabbit secondary antibody and / or Alexa Fluor 647 anti-mouse secondary antibody) prepared in the antibody diluent buffer for 3 h at RT. Tissues were then washed 3 times in PBS, 5 mins each. Coverslips (24 x 60 mm, No. 1.5H) were mounted on the glass slides using the Prolong Diamond Antifade Mountant.

[0203] Cells for the immunocytochemistry experiment were imaged using the Leica SP8 Resonant Scanning confocal microscopy with the 63x / 1 .4 oil objective. Random sampling was used to acquire 20 images per slide. Z-stacks were taken through the cells, and the maximum intensity projection image was used for analysis. Autophagy flux was calculated manually from 20 transfected cells.

[0204] Mouse tissues were acquired with Zeiss 780 confocal microscopy, using the 40x / 1.4 oil DIC M27 objective lens with 1.2 zoom. Z-stacks were taken at slice intervals of 0.34 pm. The pinhole size was set to 1 Airy Unit, and all channels had the same optical slice thickness. To process and analyse the lumbar spinal cord microscopy images for autophagy, the 3D image analysis software Imaris (version 9.7.2) was used. Firstly, 3D confocal images acquired with the Zen Black microscope software were converted with Imaris file convertor to Imaris file format. MNs were identified with 405 channel (NeuN), large cell bodies and ventral horn location. The Spot function in Imaris was then used to define red puncta using the 594 channel (RFP) as having a diameter of 0.4 pm and the green puncta using the 488 channel (GFP) as having a diameter of 0.5 pm. The values for the diameters were chosen by quantifying the diameter of a few red and green puncta and averaging them. Thethreshold was adjusted to ensure all spots were identified. The red spots quantified the number of autolysosomes per MN, and the co-localized green and red spots quantified the number of autophagosomes per MN. At least 25 MNs per mouse were analysed. The conditions of microscopic imaging and analysis were kept constant between images.

[0205] Aminotransferase (ALT) measurement in serum To measure the toxicity of the peptide in vivo, the level of alanine aminotransferase (ALT) in serum was used to measure liver toxicity. The ALT was measured using a commercially available ALT assay kit. First, 10 pL of serum samples and 0, 2, 4, 6, 8 and 10 pL of the 1 nmol / pL pyruvate standard solutions were added in duplicate to each well in a 96-well plate. Next, the samples were made up to 20 pL with ALT assay buffer. Subsequently, 100 pL of master mix reaction containing 86 pL of ALT assay buffer, 2 pL of fluorescent peroxidase substrate, 2 pL of ALT enzyme mix and 10 pL of substrate were added to each sample. The solutions were mixed using a horizontal shaker. The initial absorbance measurements (A initial) were taken at 570 nm with a 96-well plate reader (Epoch 2) at 37 °C. Absorbance measurements were taken every 5 mins until the value for the most active sample exceeded the value for the highest standard. The final measurements (A final) were the penultimate reading (the value before the most active sample exceeded the end of the linear range of the standard curve). The data were analysed by subtracting the average of A final from the averages of A initial to obtain the “Y”. The A final for standards was subtracted from standard 0 to generate a standard curve. Linear regression was used to find the equation of the straight line. The “Y” values were substituted into the equation to find “X” corresponding to the amount (nmol) of generated pyruvate. The ALT activity of the sample was then determined using the equation below: ALT activity

[0206] IgG concentration in serum

[0207] To determine whether the peptide induces inflammation in vivo, immunoglobulin G (IgG) concentration in serum was measured using a commercially available mouse IgG enzyme-linked immunosorbent assay (ELISA) kit. First, 50 pL of standards and samples diluted in the incubation buffer were added in duplicate to each well in a 96-well plate and incubated at RT for2 h on a horizontal shaker. Next, wells were washed with the wash buffertwice and then incubated with 50 pL / well of 1X horseradish peroxidase (HRP)-labelled Detector Antibody for 1 h at RT. Wells were washed with the wash buffer three times and then incubated with 50 pL / well HRP Development Solution for 10 min at RT in the dark. Finally, 50 pL / well of Stop Solution was added, and the absorbance was read at 450 nm with a 96-well plate reader (Epoch 2). The data was analysed by averaging the duplicates, subtracting from the background, and determining the concentration of IgG in samples from the standard curve.

[0208] NfL levels in serum

[0209] To measure the effect of the peptide on NfL concentration in vivo, the neurofilament light chain (NfL) concentration in serum was measured using a commercially available mouse NfL sandwich enzyme-linked immunosorbent assay (ELISA) kit. First, 50 pL of standards and samples were added in duplicate to each well in the ELISA plate, followed by 100 pL of horseradish peroxidase (HRP)-labelled Reagent. The plate was incubated at 37°C for 1 h. Subsequently, all the wells were washed four times, and 50 pL Chromogen A and 50 pL Chromogen B were added to every well and incubated at 37°C for 15 min. Finally, 50 pL of Stop Solution was added, and the absorbance was read at 450 nm with a 96- well plate reader (Epoch 2). The data was analysed by averaging the duplicates, subtracting from the background, and determining the concentration of IgG in samples from the standard curve.

[0210] Statistical analysis

[0211] Data were analysed with GraphPad Prism 9 (GraphPad Software, San Diego, CA). Results were expressed as mean + standard error of the mean (SEM) from at least 3 independent experiments. One-way ANOVA or unpaired t-tests were used to determine the difference between treatment groups. Significance was set at p<0.05.

[0212] Example 2 - Design and synthesis of BCN peptides

[0213] The Beclinl protein contains different functional domains. The ECD exists as a single globular domain, and a previous study has identified that amino acid residues from positions 267-284 (of the sequence set forth in SEQ ID NO:1) are crucial for autophagy induction by Beclinl (Shoji-Kawata et al., 2013, Nature 494:201-206). A cell-permeable analogue of this peptide, TAT-Beclin1 , was shown to induce autophagy in the peripheral tissues of adult mice and the CNS of neonatal mice 6 h post-injection at 20 mg / kg. To develop a more potent peptide analogue of ECD with the ability to induce autophagy in the CNS of adult mice, we used the x-ray crystal structure of ECD and designed 4 peptides (designated herein as BCN1 - BCN4) (see Figure 1).

[0214] The amino acid sequence of the BCN1 peptide (SEQ ID NO:5; amino acid positions 267-284 of the Beclin 1 sequence of SEQ ID NO:1) of the present study is similar to the previously published TAT- Beclin 1 peptide. However, in contrast to TAT-Beclin1 , in which 3 amino acids were substituted (H275E, S79D and Q281 E) to enhance solubility, in the present study, BCN1 with the native sequence (i.e. without the above-noted substitutions) did not give rise to any solubility issues. The amino acid sequences of the BCN2 peptide (SEQ ID NO:6; amino acid positions 263-284 of the Beclin 1 sequence of SEQ ID NO:1) and the BCN3 peptide (SEQ ID NO:4; amino acid positions 267-289 of the Beclin 1 sequence of SEQ ID NO:1) are similar to BCN1 with extension by four residues (KLKK) at the N- terminus in BCN2 or by five residues (INNFR) at the C-terminus in BCN3. The sequence of the BCN4 peptide (SEQ ID NO:3; amino acid positions 275-289 of the Beclin 1 sequence of SEQ ID NO:1) is similar to BCN3, but the random coil is truncated to only include the 3 anti- parallel p-sheets.

[0215] A previous study has shown that stapling the random coil region (resides 267- 274) induces a- helical structure and improves the autophagy-inducing activity of the peptide (Peraro et al., 2017, J Am Chem Soc 139:7792-7802). Therefore, to further enhance the activity ofthe BCN peptides, the inventors synthesised cyclic analogues of BCN1 using three different strategies as described previously (Li et al., 2002, Curr Topics Med Chem 2:325- 341 ; White et al., 2011 Nature Chem 3:509-524). The cyclisation reactions were carried out by replacing the Phe270and Thr273(i, i+3) to form the intrachain cyclic bridge. The first cyclic analogue, BCN1 (SS), was synthesised using 2,2’-Dipyridyldisulfide (DPDS) as an oxidising agent to form a disulfide bridge between free thiols of two substituted cysteines in solution (Figure 2, Scheme A). The N-terminus of BCN1 (SS) was either acetylated or protected with the chloroacetyl group (Cl.ac). The protection of the N-terminus with the Cl.ac group was based on a previous study that showed Cl.ac could enhance the cellular permeability of peptides (Perero et al. ibid). BCN1 (OX) was synthesised by cross-linking the cysteines with a dibromo-o-xylene linkerto form a nonreducible thioether bridged analogue of BCN1 (SS) (Figure 2, Scheme B). This analogue was synthesised to enhance the stability of the cyclic peptide in the cell cytoplasm’s reducing environment. The third analogue, BCN1 (EK), was synthesised by forming a lactam bond between two substituted hydrazine labile orthogonally- protected amino acids, Glu (ODmab) and Lys (iVDde) (Figure 2, Scheme C).

[0216] Previous studies (Shoji-Kawata et al. ibid', Perero et al. ibid) have shown Beclin 1 - derived peptides to have poor cellular permeability. Therefore, to increase the intracellular delivery and bioavailability of the BCN peptides, the inventors incorporated a previously developed cell-penetrating peptide (CPP) consisting of an endosomal escape domain, HA2, and a receptor-binding fragment of Apolipoprotein E (ApoE) into the BCN peptide sequences. Specifically, the CPP used herein comprises an endosomal escape domain HA2 (SEQ ID NO:9) linked by a diglycine (GG) linker to an ApoE fragment ApoE (141- 150) (SEQ ID NO:7). As used hereinbelow, in the context of the nomenclature of CPP-BCN fusion peptides, "CPP" refers to the sequence GLFHAIAHFIHGGWH-GG-LRKLRKRLLR (SEQ ID NO:11). The CPP was placed at the N-terminus of the BCN peptides. A diglycine linker (- GG-) was placed between HA2, ApoE and BCN peptides to separate the domains and impart flexibility in the peptide structure, thus allowing the peptide conjugate to adapt to the correct conformation for optimal binding to its cytosolic target.

[0217] Twenty peptides were synthesised using standard 9-Fluorenylmethoxycarbonyl (Fmoc) solidphase chemistry (see Table 2). The peptides were synthesized in high yields ranging from 36 to 84%. Peptides were charactersied by MALDI-TOF and ESI-mass spectrometry. Peptides (0.1 mmol scale) were synthesised on TentaGel® XV resin (100-200 mesh, loading: 0.20 mmol / g; Rapp Polymere). Fmoc-protected L-a-amino acids were purchased from GL Biochem (Shanghai, China). The N-terminal Fmoc protecting groups were removed by treating the resin-attached peptide with piperidine (20% v / v, Merck) in dimethylformamide (DMF). For peptides that were synthesised manually, a 5-fold molar excess of Fmoc-protected amino acids (0.5 mmol) was activated with a 5-fold excess of 1- [Bis(dimethylamino)methylene]-1 H-1 ,2 , 3-triazolo[4, 5-b] py rid in i u m 3-oxide hexafluorophosphate, hexafluorophosphate azabenzotriazole tetramethyl uranium (HATU; GL Biochem) in the presence of 10-fold excess of N, N-Diisopropylethylamine (DIEA; 1 mmol). For peptides that were synthesised on Liberty peptide synthesiser, the coupling was carried out using a 4-fold excess of Fmoc-protected amino acids (0.4 mmol) in the presence of 4-fold excess N, N'-Diisopropylcarbodiimide (DIC; Sigma-Aldrich) and 4-fold excess of Ethyl cyano(hydroxyimino)acetate (Oxyma Pure; Mimotopes) at 90 °C for 5 mins in DMF. The first amino acid and Fmoc-Arg(pbf)-OH were double coupled, and Fmoc-Cys(Trt)-OH and Fmoc-His(Trt)-OH were coupled at 50 °C for 10 mins.

[0218] Table 2 Sequence of BCN peptides, monoisotopic mass [M +H] and the percentage yields

[0219]

[0220] Example 3 - In vitro evaluation of the autophagy-inducing effect of BCN peptides

[0221] The immortalised hybrid cell line, NSC-34, composed of spinal cord motor neurons of mouse embryos fused to neuroblastoma cells, was used as an in vitro model of motor neurons to gauge the effect of BCN peptides on autophagy flux. Cells were transfected with an autophagy tandem sensor, microtubule- associated protein 1A / I B-light chain 3 (LC3) fluorescently tagged with mCherry and EGFP (mCherry- EGFP-LC3). LC3 is an essential autophagy-related protein that is cleaved to LC3-I once synthesized and lipidated to LC3-II and transferred to the phospholipid bilayer of the pre-autophagosomal structure during autophagy. LC3-II is the only protein known to be reliably associated with autophagic structures (Klionsky et al., 2021 , Autophagy 17:1-382). Upon autophagy induction, the LC3 protein tagged with the construct is inserted into the membrane of forming autophagosomes. Due to the presence of both mCherry and EGFP, autophagosomes will appear as yellow puncta in the cytosol. Once autophagosomes fuse with lysosomes, the EGFP fluorophore (pKa= 5.9) is quenched because of the pH drop. However, the mCherry fluorophore (pKa= 3.8) remains stable and allows the detection of autolysosomes as red cytosolic puncta. Therefore, the ratio of red (autolysosomes) to yellow puncta (autophagosomes) can inform the autophagy flux levels with single-cell specificity. Post-transfection, cells were treated for 24 h with 5 pM of BCN peptides and negative control peptides, including HA2, ApoE, HA2-ApoE (CPP) and CPP-Scram BCN1. Additionally, bafilomycin A1 (BafA1), which inhibits autophagy flux, was used as a negative control (0.4 pM). Rapamycin (Rapa), the most widely used autophagy inducer, was used as a positive control (0.55 pM).

[0222] As expected, treating cells for 6h with BafA1 caused an increase in autophagosome numbers by 1.6- fold leading to reduced autophagy flux by ~50% (Figure 3). Treating cells with RAPA significantly increased autophagy flux to 2-fold (p<0.05) (Figure 3). The BCN peptides without CPP showed no significant upregulation of autophagy flux. These results indicate that the CPP is essential for the cellular uptake and activity of BCN peptides. Although BCN1 (EK) showed an enhanced autophagy flux activity, it was not statistically significant (p=0.08). However, treatment with CPP-BCN3 (p<0.001) and CPP-BCN4 (p<0.05) doubled the level of autophagy flux activity compared to untreated cells. Although BCN1 (EK) showed enhanced autophagy flux activity, the difference was not statistically significant (p=0.08). Conversely, treatment with CPP-BCN3 (p<0.001) and CPP-BCN4(p<0.05) doubled the level of autophagy flux activity as they caused a 1.5-fold and 1.6-fold increase in autolysosome numbers compared to untreated cells respectively (Figure 3). Given that CPP-BCN1 and CPP-BCN2 with the two anti-parallel -strands did not induce autophagy (Figure 3), the incorporation of the three anti-parallel -strands seems to be paramount for the autophagy-inducing effect of Beclin 1-derived peptides (Figure 1).

[0223] Autophagy flux was significantly increased in cells treated with CPP-BCN3 compared to BCN3 (P<0.05), and a similar observation was made in cells treated with CPP-BCN4 compared to BCN4 (p<0.05). These results indicated that CPP improves the cellular uptake and activity of linear BCN peptides. Previous Bed in 1-derived peptides, namely TAT-11 mer, TAT-BENC1 and DD5-o, have demonstrated only autophagosomal increase at concentrations ranging from 20 to 50 pM, whereas CPP-BCN3 and CPP- BCN4 peptides were effective at increasing autophagy flux at a lower concentration of 5pM. Given that in the majority of neurodegenerative diseases, there is an over-accumulation of autophagosomes suggesting an impairment in the autolysosome formation and degradation steps (Guo, et al., 2018), it is imperative to develop autophagy-inducing peptides that are capable of promoting autolysosome formation or autophagy flux, rather than solely increasing the number of autophagosomes. Continually stimulating the synthesis of autophagosomes surpassing the rate of their processing into autolysosomes and clearance confers toxicity to cells and treatments that result in the further build-up of autophagosomes in neurons exacerbate neurodegenerative diseases (Amin, et al., (2020) Cells 9, 2413). Therefore, CPP-BCN3 and CPP-BCN4 are preferable autophagy-inducing peptides for neurodegenerative diseases as they are capable of inducing autophagy flux.

[0224] To further validate the in vitro autophagy-inducing effect the inventors chose CPP-BCN4, the shortest CPP-BCN peptide to examine its effect on the autophagy pathway at a single level. Cellular uptake of BCN4 and CPP-BCN4 was assessed at different time points using confocal microscopy. To label the peptides, a cysteine residue was placed at the N-terminus, which was conjugated to sulfo-Cy5-maleimide. The labelled peptides were purified in high yields (see Table 2).

[0225] NSC-34 cells were transfected with mCherry-EGFP-LC3 and treated with increasing concentrations of the peptide for24h. CPP-BCN4 at 20 and40 pM almost doubled the number of autolysosomes (p<0.05) without affecting the number of autophagosomes (Figure 4A and B). As a result, autophagy flux was significantly increased at 10pM(p<0.01), 20pM(p<0.001) and 40pM (p<0.05) compared to untreated (Figure 4C). This result further confirms that treatment with CPP-BCN4 promotes autophagosome-lysosome fusion and thus, autolysosome formation in a concentration-dependent manner. This is a critical step in the autophagy flux that leads to the degradation of cytosolic content such as protein aggregates collected by autophagosomes.

[0226] Autophagy is a highly dynamic process where the half-life of autophagosomes has been estimated to be approximately! 0 min. Therefore, the number of autophagosomes at any one point is the equilibrium between the rate of autophagosome synthesis and the rate of their maturation into autolysosomes and subsequent degradation. To investigate the effect of theCPP-BCN4 peptide on the autophagosome formation step, NSC-34 cells were treated with 0.4pM BafA1 , an inhibitor of lysosome acidification and autophagosome-lysosome fusion, in the absence or presence of CPP-BCN4 (20 pM). Treatment with BafA1 alone resulted in a1 ,5-foldincrease in the number of autophagosomes; however, it was not statistically significant. On the other hand, the co-treatment of BafA1 with CPP-BCN4resulted in a significant increase in the number of autophagosomes by 3.3-fold compared to untreated cells(p<0.0001) (Figure 4A and B). These results suggest that CPP-BCN4 also acts in the first stage of the autophagy flux pathway by inducing autophagosome biogenesis.

[0227] To compare the autophagy-inducing efficacy of the CPP-BCN4 peptide to the previously published TAT-BECN1 (Shoji-Kawata, et al., (2013) Nature 494, 201). NSC-34 cells were also treated with 5 and 20pM TAT-BECN1. Surprisingly, TAT-BECN1 could not increase autophagosome or autolysosome numbers (Figure 4A and B). Hence, this reported peptide did not affect autophagy flux in this cell line un the conditions of this experiment (Figure 4C). Similarly, the effect of starvation, the most common non- pharmacological approach to induce autophagy (He and Klionsky, (2009) Annual review of genetics 43), was examined in NSC-34 cells. Different methods have been used to promote starvation-induced autophagy (Castillo, et al., (2013) Cell death & disease 4, e917; Farfel-Becker, et al., (2019) Cell reports 28, 51-64. e54; Li, et al., (2014) Journal of the American Society of Nephrology 25, 305-315; Majdoul, et al., (2017) Journal of Biological Chemistry 292:18672; Tsvetkov, et al., (2009) Autophagy 5, 1037; Zhu.et al., (2017) Animal cells and systems 21 , 190-198). The inventors found that culturing cells in media without serum did not affect autophagosomes, autolysosomes or autophagy flux in NSC-34 cells (Figure 4). This is possibly due to the presence of glucose and amino acids in the media. Nevertheless, the effect of starvation on autophagy flux has been extensively studied and shown to be ineffective at increasing autophagy yin primary neurons in vitro and neurons in vivo (Mizushima et al., (2004) Mol Biol Cell 15; Tsvetkov et al., (2009) Autophagy 5).

[0228] LC3-II and the ubiquitin-associated protein p62 serve as established markers for monitoring autophagic flux. Subsequently, the inventors assessed the protein levels of LC3-II and p62 via Western blotting to ascertain the impact of CPP-BCN4 on autophagy.

[0229] The levels of LC3-II protein, which gives an estimate of the total number of autophagosomes in cells, remained unchanged compared to the untreated cells, up to concentrations of 10 pM. However, the LC3-II protein level was significantly reduced by approximately 50% at 20 pM (p<0.001) (Figure 5A and B). This result implies that the rate of autophagosome degradation exceeded the rate of autophagosome biogenesis. Similarly, the levels of another autophagy-related protein, p62, which gets incorporated into autolysosomes and undergoes degradation, inversely correlating with autophagic degradation activity 83, remained unchanged up to concentrations of 10 pM. However, its level was significantly reduced by 35% at 20 pM (p<0.001) (Figure 5A and C). Moreover, given that p62 is recruited into protein aggregates, we confirmed that its reduction in the soluble fraction is not a result of its accumulation in the insoluble fraction but, indeed, due to its degradation in autolysosomes (Figure 5D and E). Overall, these findings indicate that CPP-BCN4 enhances the entire autophagy pathway, from autophagosome formation to its fusion with lysosome and autolysosome formation and degradation.

[0230] The role of CPP-BCN4 peptides on protein aggregation in the context of neurodegenerative diseases was examined. Poly-glycine-arginine (poly-GR) is one of the five different dipeptide repeat (DPR) proteins that is abnormally expressed in Motor Neurone Disease caused by C9ORF72 mutations (C9orf72-MND) and accumulates as inclusion bodies in the brain of patients. NSC-34 cells transiently expressing EGFP- tagged 101x DPRs have revealed that poly-GA, poly-PR, and poly-GR formed puncta in NSC-34 cells in contrast to the EGFP vector and poly-PA. Given that arginine-containing DPRs are found to be the most toxic, the inventors focused on poly-GR, which forms mostly cytoplasmic puncta in NSC-34 cells.

[0231] Transfection with EGFP-poly-GR resulted in 45% of NSC-34 cells displaying cytoplasmic puncta. A 48h treatment with 10 pM of CPP-BCN4 peptide significantly reduced the number of cells containing puncta by 58% (p<0.05) (Figure 6). This result demonstrates the potential applicability of CPP-BCN4 as a candidate therapy for C9orf72-MND, given that poly-GR inclusions have been strongly correlated with neurodegeneration and clinical severity in patients.

[0232] Example 4 In vitro assessment of cell uptake of BCN peptides

[0233] To confirm that the lack of BCN4 peptide’s autophagy-inducing activity is due to its poor cell membrane permeability, the inventors studied the cellular uptake of fluorescently (Cy5)-labelled BCN4 and CPP-BCN4 at different timepoints using confocal microscopy. NSC-34cells were treated with 5pM Cy5- BCN4 or Cy5-CPP-BCN4 and live imaged. The intracellular fluorescent signal was low for Cy5-BCN4, even after 3 h of incubation (Figure 7A), whereas it was considerably higher for Cy5-CPP-BCN4, reaching saturation level after 2 h (Figure 7B). Overall, the intracellular fluorescent signal was more than 3-fold higher for Cy5-CPP-BCN4 compared toCy5-BCN4 at all time points. These data suggest that the CPP increases the cell membrane permeability and intracellular bioavailability of the BCN4 peptide and thus enhances its autophagy-inducing activity.

[0234] The ApoE peptide can bind to the low-density (LDL) superfamily receptors that are highly expressed in the human nervous system to enter cells. However, NSC-34 cells do not express LDL receptors. Therefore, without wishing to be bound by theory, the inventors suggest it is likely that the positively charged residues in ApoE peptide are interacting with the negatively charged glycosaminoglycans (GAGs) on the cell surface to carry the peptides into the cells through endosomal uptake. The HA2 peptide is an endosomal escape domain that aids the peptides in escaping endosomal compartments. Endosomal escape can occur through different mechanisms, such as pore formation in the endosomal membrane, the “proton sponge effect”, and the budding and collapse mechanism.

[0235] Example 5 - In vitro assessment of the toxicity and proteolytic stability of CPP-BCN4

[0236] The inventors have previously shown the CPP (HA2-ApoE (141-150); SEQ ID NO:11) to be safe at high concentrations (i.e. up to a concentration of 5pM; Dastpeyman et al., 2021 , Int J Pharmaceut 599:120398). However, in the current study, the CPP has been conjugated to an autophagy- inducing peptide and it may therefore have a different effect on cell viability. To determine the effect of CPP-BCN4 on cell viability, the inventors used a 3-(4,5-Dimethylthiazol-2-yl)-5(3- carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay to measure the cellular metabolic activity of NSC-34 cells treated with increasing peptide concentrations (Figure 8A). The maximal safe concentration for CPP-BCN4 was observed to be 20 pM which is four times the effective autophagyinducing concentration (5 pM). At higher concentrations of 30 and 40 pM, there was a significant reduction in the level of cell viability by 58% (13.38% + SEM) and 67% (13.38% + SEM), respectively. Without wishing to be bound by theory, it is suggested that the toxic effect at these higher concentrations may be due to excessive autophagy upregulation resulting in autophagy-mediated or autophagy-dependent cell death.

[0237] To guide in vivo studies, the stability of CPP-BCN4 was also assessed by incubating the peptide in a commercially available human serum. The percentage of intact peptide remaining at different time points were determined using RP-HPLC. The half-life of CPP-BCN4 was determined to be ~39 min (Figure 8B), which was expected as peptides typically have half-lives between 5 min to 2 h in serum-based assays.

[0238] These in vitro results suggest that CPP-BCN4 may be advantageously administered at low and repeated doses to ensure sufficient amounts of the peptide are taken up by target tissues to significantly upregulate autophagy flux and, thus, achieve the desired therapeutic outcome.

[0239] Example 6 - In vivo evaluation of the autophagy activity of CPP-BCN4

[0240] The central nervous system (CNS) is the main target site for the upregulation of autophagy as a potential therapeutic avenue for neurodegenerative diseases. To evaluate CNS uptake and autophagyinducing activity of the CPP-BCN4 peptide, the inventors used an autophagy reporter mouse model expressing the red fluorescent protein (RFP)- enhanced green fluorescent protein (EGFP)-LC3 fusion protein in tandem underthe cytomegalovirus immediate early enhancer / chicken p actin (CAG) promoter (Li et al., 2017, Acta Crystallogr D Struct Biol 73:775-792), which has been used to study autophagy flux in various tissues.

[0241] The RFP-EGFP-LC3 mice at 2 months of age were administered with saline or CPP- BCN4 peptide over 1 week via two different routes. CPP-BCN4 at 10 pg / day was administered into the CNS at a controlled and constant rate through the intraventricular (ICV) route, resulting in no loss of the peptide to peripheral tissues. However, ICV infusion may not be suitable for long-term therapy. Therefore, three doses of the peptide at 10 mg / kg were also administered via intravenous (IV) injections. The doses were established as the maximum tolerable dose through a dose-escalation study (5 and 10 pg / day for ICV and 10 and 20 mg / kg for IV).

[0242] The level of autophagy flux was analysed in spinal motor neurons (MNs) of mice. The MNs in the lumbar spinal cord were identified based on NeuN labelling, and autophagy activity was quantified using the Imaris 3D image analysis software.

[0243] Although the results of short-term (1 week) treatment of RFP-EGFP-LC3 mice showed a trend toward upregulation of autophagy, the level of autophagy flux in the MNs was not significant (data not shown). Therefore, the inventors treated the 2-month-old adult mice for a more extended period of 2 weeks via ICV infusion or 3 weeks with 2 doses / week via IV injections. The analysis of at least 25 lumbar spinal MNs / mice (n= 5-6 mice) showed that the CPP-BCN4 significantly increased the number of autolysosomes by ~1.5 and ~2-fold compared to saline for ICV infusion and IV injections, respectively (p<0.05, Figure 7 and Figure 10A and 8B).

[0244] The CPP-BCN4 also significantly increased the number of autophagosomes per MNs by -1.7- fold for ICV infusion and non-significantly by ~2.5-fold for IV injections (Figure 9 and Figure 10A and 10B). Consequently, the effect of CPP-BCN4 was not apparent in the autophagy flux data (Figure 9 and Figure 10A and 10C). As expected, the negative control peptide, CPP-Scram BCN4, did not affect the number of autophagosomes and autolysosomes (Figure 10A and 10B).

[0245] The size of autophagy vesicles provides an indication of the state of autophagy activity. For example, an increase in the size of autophagosomes and autolysosomes can suggest a dysfunction in the degradation process (Kim et al., 2020, BMB Reports 53:241). Quantifying the volume of RFP+ vesicles (representing both autophagosomes and autolysosomes), the inventors found a significantly reduced volume of autophagic vesicles in mice i.v. treated with CPP-BCN4 (Figure 10D) compared to saline. This result suggests that the CPP-BCN4 peptide increased the degradative capacity of MNs, preventing the accumulation of undigested cargo within autophagosomes and autolysosomes.

[0246] For the completion of autophagy, lysosomes need to fuse with autophagosomes. Therefore, to investigate whether the lysosomal availability in cells affected the autophagy flux results, the number of lysosomes per MNs was also quantified by labelling for the lysosomal- associated membrane protein 1 (LAMP1). Compared with saline, treatment with CPP-BCN4 via ICV infusion and IV injections significantly increased LAMP1 levels (p<0.01 , Figure 11A and 11 B). Therefore, the peptide increases the rate of LAMP1- positive lysosomal biogenesis, possibly by increasing the rate of autophagic lysosome reformation (ALR), the terminal step of the autophagy pathway where lysosomes emanate from autolysosomes. The above results collectively suggest that ALR is enhanced with CPP-BCN4 treatment.

[0247] Moreover, the number of autophagic vesicles (RFP+puncta) co-localised with lysosomes (LAMP1+puncta) was also significantly increased following treatment with CPP- BCN4 via IV injections (p<0.05, Figure 11A and 11 C), indicating that more of the lysosomes are recruited to the autophagy pathway following peptide treatment.

[0248] Taken together, these results provide strong evidence that the BCN4 peptide is reaching the MNs in the CNS following systemic administration and successfully enhancing the autophagy pathway, from autophagosomes to autolysosomes and lysosomes. Therefore, compared to other Beclinl-derived peptides that only increased the number of autophagosomes at 15-20 mg / kg, the CPP-BCN4 peptide of the present study is superior as it successfully increased autophagy activity at 10 pg / day via ICV infusion and 10 mg / kg via IV injection in the CNS of adult mice.

[0249] Example 7 - In vivo assessment of the toxicity of CPP-BCN4

[0250] To assess the in vivo toxicity of CPP-BCN4, blood serum from RFP-EFP-LC3 mice ICV infused with the peptide for 2 weeks or IV injected with the peptides for 3 weeks was analysed for the level of alanine transaminase (ALT), a marker of liver toxicity. Since the liver is one of the major organs that gets exposed to the peptide, it is an appropriate organ to assess for systemic toxicity of the peptide treatment. CPP-BCN4 and CPP-Scram BCN4 peptide treatment did not affect the level of serum ALT compared to the saline-treated group (Figure 12A). Furthermore, repeated IV injections of CPP-BCN4 did not change immunoglobulin G (IgG) levels, a marker of activated humoural immunity and inflammation compared to saline-treated group (Figure 12B). These results suggest that the peptides at the effective dose are safe and well tolerated following ICV and IV administration.

[0251] Example 8 Effect of different BCN constructs on autophagy flux

[0252] Different BCN peptides were generated and tested for their activity on autophagy flux. These constructs are summarized in the following Table (Table 3).

[0253] Table 3 BCN peptide constructs

[0254] The effect of the BCN4 peptides on autophagy flux was examined in vitro according to the methods described herein. The ratio of autolysosomes to autophagosomes was compared in NSC-34 cells transfected with the mCherry-EGFP-LC3 reporter construct and subsequently treated 24h later with the BCN peptides for 24h. The results are shown in Figure 16. Changing the length of the ApoE sequence or the spacer did not demonstrably affect autophagy flux.

[0255] Remarks

[0256] The inventors demonstrated that short peptides derived from the ECD of endogenous Beclinl protein could effectively increase autophagy and reduce MND-associated poly-GR protein puncta in MN-like cells in vitro. The conjugation of a novel CPP developed by the inventors to the peptides enhanced their cytosolic bioavailability and autophagy flux activity. Furthermore, the in vivo study of the most potent peptide with the minimum active sequence, CPP-BCN4, showed a significant increase in the level of autophagy activity in the CNS following ICV and IV administrations. Although both routes of peptide administration produced similar levels of autophagy activity in the spinal MNs, the IV route of delivery is preferable in practice, which is non-invasive compared to the invasive intrathecal route of CNS delivery currently employed in the clinic for direct CNS administration of biologies. Therefore, this study reports a novel BBB-penetrating peptide analogue of Beclinl ECD that can increase autophagy at multiple steps. Moreover, the present research highlighted the importance of duration and route of administration for achieving a significant increase in the level of autophagy activity in the CNS.

Claims

Claims1. An isolated peptide comprising:(i) at least one cell penetrating peptide (CPP) sequence comprising(a) an endosomal escape domain (EED) sequence; and(b) an apolipoprotein A (ApoE) sequence; and(ii) at least one sequence comprising up to about 30 contiguous amino acid residues derived from an evolutionary conserved domain (ECD) of a Beclin-1 peptide (BCN) or analogue or derivative thereof.

2. The peptide according to claim 1 , wherein the Beclin-1 sequence or analogue thereof is derived from amino acid residues 263 to 289 of the human Beclin-1 sequence set forth in SEQ ID NO:1.

3. The peptide according to claim 1 or 2, wherein the Beclin-1 peptide or analogue thereof comprises or consists of the sequence HIWHSGQFGT (SEQ ID NO:2).

4. The peptide according to any one of claims 1 to 3, wherein the EED sequence comprises a peptide sequence comprising a pH-dependent endosomal membrane disrupting moiety.

5. The peptide according to claim 4, wherein the EED peptide comprises an N-terminal fragment of the influenza virus hemagglutinin subunit HA2, a GALA peptide or a nuclear localisation sequence.

6. The peptide according to claim 5, wherein the HA2 peptide comprises the amino acid sequence set forth in GLFHAIAHFIHGGWH (SEQ ID NO:9), a derivative thereof, or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto.

7. The peptide according to any one of claims 1 to 6, wherein the ApoE sequence is a fragment peptide comprising the sequence set forth in LRKLRKRLLR (SEQ ID NO:7) or the sequence set forth in LRVRLASHLRKLRKRLLR (SEQ ID NO:8).

8. The peptide according to any one of claims 1 to 7, further comprising an active agent.

9. The peptide according to any one of claims 1 to 8, wherein the at least one CPP peptide is conjugated or linked to the N or C-terminus of the at least one BCN peptide or analogue or derivative thereof.

10. The peptide according to any one of claims 1 to 9, wherein the CPP and BCN1 peptides are linked by a linker sequence.

11. The peptide according to any one of claims 1 to 10, wherein the CPP comprises the sequence GLFHAIAHFIHGGWH-GG-LRKLRKRLLR (SEQ ID NO:11).

12. The peptide according to any one of claims 1 to 11 , wherein the Beclin-1 peptide or derivative comprises or consists of a sequence selected from the group consisting of (i) TNVFNATFHIWHSGQFGT (BCN1 ; SEQ ID NO:5), (ii) KLKKTNVFNATFHIWHSGQFGT (BCN2; SEQ ID NO:6), (iii) TNVFNATFHIWHSGQFGTINNFR (BCN3; SEQ ID NO:4) or (iv) HIWHSGQFGTINNFR (BCN4: SEQ ID NO:3).

13. The peptide according to any one of claims 1 to 12, wherein the peptide comprises a sequence selected from the group consisting of (i) GLFHAIAHFIHGGWH-GG-LRKLRKRLLR-GG- HIWHSGQFGTINNFR (SEQ ID NO:13), GLFHAIAHFIHGGWH-GG-LRKLRKRLLR-GG- TNVFNATFHIWHSGQFGTINNFR (SEQ ID NO:14), GLFHAIAHFIHGGWH-GG-LRKLRKRLLR-GG- TNVFNATFHIWHSGQFGT (SEQ ID NO:15) and GLFHAIAHFIHGGWH-GG-LRKLRKRLLR-GG- KLKKTNVFNATFHIWHSGQFGT (SEQ ID NO: 16) or a sequence at least 90% identical thereto.

14. The peptide according to any one of claims 1 to 13, wherein the peptide comprises the sequence set forth in GLFHAIAHFIHGGWH-GG-LRKLRKRLLR-GG-HIWHSGQFGTINNFR (SEQ ID NO:13).

15. The peptide according to any one of claims 1 to 14, wherein the peptide is in the form of a pharmaceutical composition.

16. An isolated peptide according to claim 1 comprising:(i) a sequence comprising an endosomal escape domain;(ii) a sequence comprising the amino acid sequence set forth in SEQ ID NO:7 or 8 or a sequence having at least or about 90% sequence identity thereto; and(iii) a sequence of up to about 30 contiguous amino acid residues of the Beclin-1 sequence set forth in SEQ ID NO:1 , wherein the contiguous amino acid residues comprise or consist of residues between positions 263-289 of SEQ ID NO:1.

17. The peptide of claim 16, comprising from N-terminus to C-terminus, sequence (i), sequence (ii), and sequence (iii), optionally wherein a linker separates sequence (i) and sequence (ii) and / or a linker separates sequence (ii) and sequence (iii).

18. The peptide of claim 16 or 17, wherein the linker comprises a diglycine (GG) linker.

19. The peptide of any one of claims 16 to 18, wherein sequence (iii) comprises the amino acid sequence of SEQ ID NO:2 or a sequence having at least or about 90% sequence identity thereto.

20. An isolated peptide comprising a sequence of up to about 30 contiguous amino acid residues of the Beclin-1 sequence set forth in SEQ ID NO:1 , wherein the contiguous amino acid residues comprise or consist of residues between positions 263-289 of SEQ ID NO:1 , wherein the peptide does not contain the substitutions H275E, S279D and Q281 E, and wherein the peptide is capable of inducing autophagy in a cell.21 . The peptide of claim 20, wherein the contiguous amino acid residues comprise or consist of:(i) residues at positions 275-284 of SEQ ID NO:1 ;(ii) residues at positions 275-289 of SEQ ID NO:1 ;(Hi) residues at positions 267-289 of SEQ ID NO:1 ;(iv) residues at positions 267-284 of SEQ ID NO:1 ; or(v) residues at positions 263-284 of SEQ ID NO:1 .

22. An isolated peptide comprising or consisting of the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6.

23. The peptide of any one of claims 20 to 22, wherein the peptide is linked to a cell-penetrating peptide sequence.

24. The peptide of claim 23, wherein the cell-penetrating peptide sequence comprises a fusion peptide comprising (i) an endosomal escape domain, and (ii) a peptide sequence comprising the amino acid sequence set forth in SEQ ID NOT or 8 or a sequence having at least or about 90% sequence identity thereto.

25. The peptide of claim 24, wherein the cell-penetrating peptide sequence comprises or consists of the sequence set forth in SEQ ID NO:10, SEQ ID NO:11 or SEQ ID NO:12.

26. A method for inducing autophagy in a cell, comprising exposing the cell to a peptide of any one of claims 1 to 25.

27. A method for inducing autophagy in one or more cells in a subject, comprising administering to the subject a peptide of any one of claims 1 to 25.

28. The method of claim 27, wherein the subject has a disease or condition associated with impaired autophagy in one or more cells, optionally in cells of the central nervous system.

29. The method of claim 28, wherein the subject has a neurodegenerative disease.

30. The method of claim 29, wherein the neurodegenerative disease is selected from Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, amyotrophic lateral sclerosis and a tauopathy.

31. A method for treating or preventing a condition associated with impaired autophagy, comprising administering to a subject in need thereof a peptide of any one of claims 1 to 25.

32. The method of claim 31 , wherein the disease or condition is selected from cancer, a cardiovascular disease, a disease of the liver or kidneys, a disease or condition associated with aging, an immune systemdisorder, an autoimmune disease, a muscular disease, a metabolic disorder, an inflammatory disease, an ocular disease, an infectious disease, a neurological disease and a neurodegenerative disease.

33. The method according to claim 32, wherein the ocular disease is glaucoma.

34. A method for treating or preventing a neurodegenerative disease, comprising administering to a subject in need thereof a peptide of any one of claims 1 to 25.

35. The method of claim 33, wherein the neurodegenerative disease is selected from Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, amyotrophic lateral sclerosis and a tauopathy.

Citation Information

Patent Citations

  • Autophagy-inducing peptide

    WO2013119377A1

  • Compositions and methods for improving viral vector efficiency

    WO2017093330A1

  • Method to restore or improve cognitive functions

    WO2020070235A1